WO2014104246A1 - 高機能インプラント材料 - Google Patents
高機能インプラント材料 Download PDFInfo
- Publication number
- WO2014104246A1 WO2014104246A1 PCT/JP2013/084990 JP2013084990W WO2014104246A1 WO 2014104246 A1 WO2014104246 A1 WO 2014104246A1 JP 2013084990 W JP2013084990 W JP 2013084990W WO 2014104246 A1 WO2014104246 A1 WO 2014104246A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- implant
- cell
- culture
- cell product
- Prior art date
Links
- 239000007943 implant Substances 0.000 title claims abstract description 141
- 239000000463 material Substances 0.000 title claims abstract description 60
- 210000004027 cell Anatomy 0.000 claims abstract description 196
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 31
- 210000000130 stem cell Anatomy 0.000 claims abstract description 30
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 239000010936 titanium Substances 0.000 claims description 61
- 239000000047 product Substances 0.000 claims description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 239000002609 medium Substances 0.000 claims description 49
- 239000012228 culture supernatant Substances 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 27
- 230000002308 calcification Effects 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 22
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 21
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 20
- 239000002244 precipitate Substances 0.000 claims description 20
- 210000000689 upper leg Anatomy 0.000 claims description 19
- 239000012091 fetal bovine serum Substances 0.000 claims description 18
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 17
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 15
- 229910052719 titanium Inorganic materials 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229960005322 streptomycin Drugs 0.000 claims description 14
- 108090000738 Decorin Proteins 0.000 claims description 13
- 102000004237 Decorin Human genes 0.000 claims description 13
- 229930182555 Penicillin Natural products 0.000 claims description 13
- 238000004140 cleaning Methods 0.000 claims description 13
- 229940049954 penicillin Drugs 0.000 claims description 13
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 11
- 210000004489 deciduous teeth Anatomy 0.000 claims description 11
- 108010085238 Actins Proteins 0.000 claims description 10
- 102000007469 Actins Human genes 0.000 claims description 10
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 10
- 238000007654 immersion Methods 0.000 claims description 9
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims description 9
- 102000012422 Collagen Type I Human genes 0.000 claims description 8
- 108010022452 Collagen Type I Proteins 0.000 claims description 8
- 238000012869 ethanol precipitation Methods 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 7
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 6
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims description 5
- 239000012888 bovine serum Substances 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims description 5
- 108010001535 sulfhydryl oxidase Proteins 0.000 claims description 5
- 102100029379 Follistatin-related protein 3 Human genes 0.000 claims description 4
- 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 claims description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 claims description 3
- 101710179387 Collagen alpha-2(IV) chain Proteins 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 3
- 102100027655 Rho GTPase-activating protein 18 Human genes 0.000 claims description 2
- 101710110410 Rho GTPase-activating protein 18 Proteins 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims 2
- ICSSIKVYVJQJND-UHFFFAOYSA-N calcium nitrate tetrahydrate Chemical compound O.O.O.O.[Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ICSSIKVYVJQJND-UHFFFAOYSA-N 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 56
- 239000003102 growth factor Substances 0.000 abstract description 32
- 102000016359 Fibronectins Human genes 0.000 abstract description 13
- 239000008267 milk Substances 0.000 abstract 2
- 210000004080 milk Anatomy 0.000 abstract 2
- 235000013336 milk Nutrition 0.000 abstract 2
- 230000001089 mineralizing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 52
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 37
- 239000002953 phosphate buffered saline Substances 0.000 description 37
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 26
- 241000700159 Rattus Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 15
- 230000001464 adherent effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 11
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 230000010354 integration Effects 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 241000701161 unidentified adenovirus Species 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 210000005258 dental pulp stem cell Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 210000001968 dental pulp cell Anatomy 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 7
- 230000021164 cell adhesion Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000004544 DNA amplification Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 210000000845 cartilage Anatomy 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 238000009832 plasma treatment Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 101000613820 Homo sapiens Osteopontin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100031475 Osteocalcin Human genes 0.000 description 5
- 102100040557 Osteopontin Human genes 0.000 description 5
- 102000013275 Somatomedins Human genes 0.000 description 5
- 238000004115 adherent culture Methods 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 5
- 210000003632 microfilament Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101800001318 Capsid protein VP4 Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108010009711 Phalloidine Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 4
- -1 SPARC Proteins 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 102100035071 Vimentin Human genes 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 3
- 102000017304 72kDa type IV collagenases Human genes 0.000 description 3
- 108050005269 72kDa type IV collagenases Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 102100021253 Antileukoproteinase Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 101710153276 Insulin-like growth factor-binding protein 7 Proteins 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 108090000573 Osteocalcin Proteins 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 102000004264 Osteopontin Human genes 0.000 description 3
- 108010081689 Osteopontin Proteins 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 238000010165 Scheffé test Methods 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000003074 dental pulp Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 108010043137 Actomyosin Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
- 101710126238 Collagen alpha-2(I) chain Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 239000004107 Penicillin G sodium Substances 0.000 description 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 2
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 101000635917 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Myosin-1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100025252 StAR-related lipid transfer protein 13 Human genes 0.000 description 2
- 102100034371 Sulfhydryl oxidase 1 Human genes 0.000 description 2
- 101710159725 Sulfhydryl oxidase 1 Proteins 0.000 description 2
- 102100036236 Synaptonemal complex protein 2 Human genes 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000019369 penicillin G sodium Nutrition 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000000955 peptide mass fingerprinting Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 108010004650 rho GTPase-activating protein Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- PWVRXSQPCQPQHM-UHFFFAOYSA-N 2-(4-aminophenyl)-1h-indol-6-amine Chemical compound C1=CC(N)=CC=C1C1=CC2=CC=C(N)C=C2N1 PWVRXSQPCQPQHM-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 101150080498 ALP gene Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 102000003730 Alpha-catenin Human genes 0.000 description 1
- 108090000020 Alpha-catenin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 101150079550 BSP gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 238000012756 BrdU staining Methods 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102100031544 Collagen alpha-1(XXVII) chain Human genes 0.000 description 1
- 101710161374 Collagen alpha-1(XXVII) chain Proteins 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 208000002354 Edentulous Jaw Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101001000207 Equus caballus Decorin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101000692347 Penicillium olsonii Polygalacturonase 2 Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 108010001953 Protein C Inhibitor Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102100032889 Sortilin Human genes 0.000 description 1
- 101000730868 Sus scrofa Protegrin-2 Proteins 0.000 description 1
- 108030003984 Thiol oxidases Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 108010048992 Transcription Factor 4 Proteins 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 108090000384 Vinculin Proteins 0.000 description 1
- 102000003970 Vinculin Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 101710204001 Zinc metalloprotease Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004068 calcium phosphate ceramic Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 108010040063 dermatan sulfate proteoglycan Proteins 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 108010092028 endopolygalacturonase II Proteins 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000001621 ilium bone Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010057670 laminin 1 Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 102000034272 protein filaments Human genes 0.000 description 1
- 108091005974 protein filaments Proteins 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000035736 spondylodysplastic type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000034926 vesicle transport along actin filament Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0664—Dental pulp stem cells, Dental follicle stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0669—Bone marrow stromal cells; Whole bone marrow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Definitions
- the present invention relates to a highly functional implant material using a product of bone marrow stromal cells (BMCs) or immortalized deciduous stem cells. More specifically, the present invention relates to a highly functional implant material having a surface coated with a product of the BMCs bone marrow stromal cells or immortalized deciduous teeth stem cells.
- BMCs bone marrow stromal cells
- One purpose of dental treatment is to restore the function and shape of the missing tooth using artificial materials. For this reason, implants are used as the most common treatment to make up for missing teeth and the like. Originally, since it is necessary to stabilize the implant in order to exert a sufficient function on the missing tooth or the like, it is desirable that the implant be integrated with the alveolar bone. For this reason, bioglass, calcium phosphate ceramics (ie, hydroxyapatite and ⁇ -tricalcium phosphate) and other bioactive materials and metal materials have been used as such implant materials.
- the above-mentioned bioactive materials are excellent in that they are highly biocompatible.
- the metal material is superior from the viewpoint of mechanical properties such as strength and durability.
- titanium hereinafter sometimes referred to as “Ti”) is widely used as an implant material in terms of biocompatibility and cost.
- the prior art described above is superior in that integration into bone is progressing compared to the case where the surface of the metal implant material is not treated.
- the treatment of the surface of the metal implant material is performed by a procedure of first performing a pretreatment for activating the surface of the metal implant and then treating with a bone formation reagent or applying a growth factor, so that the operation is complicated. there were.
- a growth factor is applied to the surface of the metal implant material, the period during which the growth factor fixed on the surface is retained becomes a problem. This is because sufficient integration cannot be expected if the period of time held on the surface of the metal implant material is shorter than the time required for integration of the bone and the metal implant material.
- 5 ⁇ 10 3 to 5 ⁇ 10 4 is contained in a culture solution containing 5 to 15% serum, 50 to 150 U / mL penicillin and 50 to 150 ⁇ g / mL streptomycin.
- Cells having a predetermined shape and adhesion; a preculture step in which bone marrow stromal cells or immortalized deciduous dental stem cells are added and precultured in the presence of 34% to 37.5 ° C and 5% CO 2 ;
- a method for preparing a product is described in a culture solution containing 5 to 15% serum, 50 to 150 U / mL penicillin and 50 to 150 ⁇ g / mL streptomycin.
- the bone marrow stromal cells are preferably obtained from rat femur, and the immortalized dental pulp stem cells are derived from any cell selected from the group consisting of porcine pulp and human deciduous teeth. Is preferred.
- the cells are preferably cultured at 37 ° C.
- the predetermined shape in the cell sorting step is preferably a spindle shape and a spindle shape.
- the culture supernatant is preferably collected 44 to 52 hours after the start of culture, and more preferably 48 hours after the start of culture.
- the culture solution is preferably at least one medium selected from the group consisting of Dulbecco medium, Iskov modified Dulbecco medium, Ham F12 medium, and RPMI1640 medium.
- the serum is preferably at least one serum selected from the group consisting of fetal bovine serum, bovine serum, horse serum, human serum, and sheep serum.
- the culture solution preferably contains 10% fetal bovine serum, 100 U / mL penicillin, and 100 ⁇ g / mL streptomycin.
- the preparation method may further include a precipitate adjustment step of preparing a precipitate by performing centrifugation and ethanol precipitation, and a freeze-drying step of freeze-drying the precipitate obtained in the precipitate preparation step. preferable.
- the second aspect of the present invention is a cell product prepared by the preparation method described above.
- the cell product preferably contains at least type I collagen (Col-I), fibronectin, decorin, and vascular endothelial growth factor (VEGF).
- VEGF vascular endothelial growth factor
- insulin-like growth factor binding protein 7 follistatin Additional proteins, metalloproteinase inhibitor I, tissue plasminogen activator inhibitor, actin, and sulfhydryl oxidase I, SPARC, collagen ⁇ 2 (IV) chain, ⁇ -2-microglobulin, Rho GTPase activating protein 18 Is even more preferable.
- the present invention also provides a cleaning step in which the surface of the implant material is cleaned with an organic solvent to form a cleaning implant material; and the cleaning implant material is placed in a first calcification solution having a predetermined composition at a predetermined temperature for 3 to 6 A dipping step of dipping for a time to obtain a dipped implant material; and a treatment step of incubating the dipped implant material with a second calcification solution containing a cell product at a predetermined concentration for 2 to 5 days.
- This is a method for creating a highly functional implant.
- the implant material is preferably made of any material selected from the group consisting of titanium, zirconia, hydroxyapatite, and ⁇ -TCP.
- the organic solvent is preferably acetone and 60-80% ethanol.
- the first calcification solution is 100 to 150 mM NaCl, 2.5 to 3.5 mM CaCl 2 ⁇ H 2 O, 1.5 to 2.5 mM K 2 HPO 4 , 25 to 75 mM Tris-HCl (pH 7.2 to 7.6). 136.8 mM NaCl, 3.10 mM CaCl 2 .H 2 O, 1.86 mM K 2 HPO 4 , 50 mM Tris-HCl (pH 7.4) is more preferred.
- the predetermined temperature is 36 to 38 ° C. and the immersion time is 4 hours.
- the predetermined cell product is preferably an aqueous solution of 5 to 20 mg / mL of the above cell product, and more preferably about 10 mg / mL.
- the third aspect of the present invention is a highly functional implant produced by any of the methods described above.
- the implant material is preferably formed of any material selected from the group consisting of titanium, zirconia, hydroxyapatite, and ⁇ -TCP.
- the implant preferably retains at least type I collagen (Col-I), fibronectin, and decorin on the surface, and includes insulin-like growth factor binding protein 7 (IGF-binding protein 7), follistatin-related protein, More preferably, the surface further has at least one protein selected from the group consisting of metalloproteinase inhibitor I, tissue plasminogen activator inhibitor, actin, and sulfhydryl oxidase I.
- a cellular product containing can be prepared.
- a highly functional implant can be produced simply using this cell product.
- a highly functional implant material that can be integrated with bone in a short period of time can be obtained.
- FIG. 1 is an electron micrograph of the surface of a Ti implant taken using a scanning electron microscope (SEM).
- SEM scanning electron microscope
- FIG. 1 (A) and (D) are surfaces treated with PBS (phosphate buffered saline), and (B) and (E) are treated with DMEM (Dulbecco's ⁇ -MEM).
- Surfaces (C) and (F) show the surfaces treated with CM (culture supernatant of cell culture).
- FIG. 2 shows the number of cells that were seeded with 1.0 ⁇ 10 6 cells on the surface of a Ti implant (hereinafter sometimes referred to as “Ti plate”) treated as described above and adhered after 24 hours. It is a figure (ANOVA test. In the figure, * indicates p ⁇ 0.05).
- FIG. 3 shows gel electrophoresis images (A) to (C) of rat BMSCs cultured on a Ti plate surface having immobilized DMEM or CM, and graphs quantifying the gels (D) to (F). It is.
- FIG. 4 is a detection image of QD-labeled biomolecules on Ti implants in vivo.
- PBS, DMEM and CM are as described above.
- FIG. 5 is a graph showing the relationship between the immortalized stem cells selected from the above-described dental pulp cells, the number of individual doublings of cells that are not immortalized stem cells, and the culture period.
- SHED-T represents an immortalized stem cell
- SHED-C represents a cell that is not an immortalized stem cell.
- FIG. 6 is a graph showing the results of STRO-1 expression in SHED-C and SHED-T (FIGS. 2 (A) to (D)).
- FIG. 7 is a diagram showing tissue staining images of SHED-C and SHED-T at the individual doubling time shown in FIG.
- FIG. 8 is a graph showing the relationship between the individual doubling time (number of times) and the amount of new bone, in which ** represents p ⁇ 0.05 and *** represents p ⁇ 0.01.
- the amount of new bone was determined by the following calculation formula.
- New bone mass New bone area / field of view x 100
- P represents a case where plasma treatment is performed under atmospheric pressure
- N represents a case where plasma treatment is not performed.
- * indicates p ⁇ 0.05
- ** indicates p ⁇ 0.01.
- the scale bar indicates 100 ⁇ m.
- the preparation method of the present invention comprises (a) 5 ⁇ 10 3 to 5 ⁇ 10 4 cells in a culture solution containing 5 to 15% serum, 50 to 150 U / mL penicillin and 50 to 150 ⁇ g / mL streptomycin.
- the culture solution is Dulbecco's medium (hereinafter sometimes referred to as “DMEM”), Iskov modified Dulbecco's medium (hereinafter sometimes referred to as “IMDM”), Ham F12 medium (hereinafter referred to as “Ham12”) And at least one medium selected from the group consisting of RPMI1640 medium is preferable because it is easy to obtain and handle.
- the above medium is a medium called a basic medium and can be purchased from GIBCO, SIGMA, or the like. Of these media, two or more types can be used in combination as a mixed medium.
- the mixed medium a medium in which IMDM and HamF12 are mixed in equal amounts (for example, commercially available as trade name: IMDM / HamF12 (GIBCO)) can be mentioned.
- the serum is at least one serum selected from the group consisting of fetal bovine serum, bovine serum, horse serum, human serum, and sheep serum. This is preferable because no protein is produced in the culture supernatant.
- serum substitutes Knockout serum replacement (KSR), etc.
- bovine serum albumin BSA
- penicillin streptomycin
- gentamicin gentamicin
- vitamin K folic acid
- the present invention also includes (d) a precipitate preparation step for preparing a precipitate by performing centrifugation and ethanol precipitation; (e) a freeze-drying step for freeze-drying the precipitate obtained in the precipitate preparation step; Can be further provided.
- the bone marrow stromal cells are derived from any cell selected from the group consisting of rat femur, porcine lower jaw and teeth, and human deciduous teeth. It is preferable because cells that can be produced are surely available.
- the cell growth factor is a general term for polypeptide factors involved in proliferation, differentiation and the like of specific cells, and also includes lymphokines and cytokines that regulate the immune system. Sometimes called growth factor or cell growth factor.
- growth factor is sometimes simply referred to as “growth factor”.
- Growth factors are known to be involved in the regulation of various cytological and physiological processes in vivo, and receptor proteins (hereinafter simply referred to as “receptors” or “receptors”) on the surface of target cells. It is specifically bound to ”) and performs signal transduction.
- Typical growth factors include epidermal growth factor (EGF), insulin-like growth factor (IGF), transforming growth factor (TGF), nerve growth factor (Nerve) growth factor (NGF), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), granulocyte-colony factor (G-CSF) ), Granulocyte-macrophage-colony-stimulating factor (GM-CSF), platelet-derived growth factor (PDGF), erythropoietin (EPO), thrombopoietin (TPO), base Fibroblast growth factor (basic fibroblast growth factor: bFGF or FGF2), hepatocyte growth factor (Hepatocyte growth fact) or: HGF).
- EGF epidermal growth factor
- IGF insulin-like growth factor
- TGF nerve growth factor
- NGF nerve growth factor
- BDNF brain-derived neurotrophic factor
- VEGF vascular endothelial growth factor
- G-CSF Granul
- TGF- ⁇ is one of the growth factors existing in nature. Like many other signal pathways, it plays a vital role in device development, cell differentiation, and embryo development. ⁇ -type mutant growth factor TGF- ⁇ is produced in almost all cells such as kidney, bone marrow, and platelets, and there are five subtypes ( ⁇ 1 to ⁇ 5). TGF- ⁇ 1 to ⁇ 3 are accumulated in an inactive form in the bone matrix, and are activated by acids released by osteoclasts during bone resorption. TGF- ⁇ promotes the proliferation of osteoblasts and the synthesis and proliferation of mesenchymal cells such as collagen, but acts on epithelial cells and osteoclasts in a suppressive manner.
- the tyrosine residue in the protein is phosphorylated by binding of the growth factor, and cell proliferation / differentiation is induced.
- growth factors are mesoderm inducers during ontogeny.
- the above growth factors fall into several families that are related in terms of their structure and evolution. Examples of these families include TGF- ⁇ , bone morphogenic protein (BMP), neurotrophin (neurotrophic factor), fibroblast growth factor (FGF) and the like.
- the neurotrophic factors include NGF, BDNF, NT3 and the like. Growth factors are now actively used in medicine.
- TGF- ⁇ is a member of the TGF- ⁇ superfamily, and this superfamily includes bone morphogenetic protein (BMP), which plays an important role in bone formation in organisms. Is included.
- BMP bone morphogenetic protein
- the culture supernatant of the present invention includes collagen ⁇ -1 (I) chain, collagen ⁇ -2 (I) chain, vimentin, collagen ⁇ -1 (IV) chain, IGF binding protein 7 (IGFBP7), fibronectin, decorin, Plasminogen activator inhibitor 1, actin (cytoplasmic 2), sulfhydryl oxidase 1, SPARC, metalloproteinase inhibitor 1, collagen ⁇ -2 (IV) chain, SCP2, 72kDa type IV collagenase, ⁇ -2-microglobulin, Rho It is preferable that various proteins such as GTPase activating protein 18 are included.
- collagen is a molecule having a triple helix structure composed of three ⁇ chains, and it is known that there are many types such as type I, type II, type III, type IV, and type V. Each type of molecule consists of the same or different types of polypeptide chains. It is known that there are 30 or more types of polypeptide chains ( ⁇ chains), and they are called ⁇ 1 (I), ⁇ 2 (IV) and the like.
- the collagen protein family is classified as follows. 1) Specific group of molecules that form fibers with a periodic striated structure of 67 nm (type I, type III, type V (mainly tissues other than cartilage)), type II, type XI (cartilage tissue)
- Molecule groups (XII type, XIV type (non-cartilage tissue), IX type (cartilage tissue)) bound to the surface of these fibers 3) A group of molecules that form a network-like aggregate (type IV collagen that mainly forms the basement membrane skeleton), type VI that forms extracellular fine fibers, and a basement plate from epidermal basal cells such as skin.
- Type VII that forms anchoring fibrils that penetrate through 4)
- Type X that forms hexagonal lattice (present temporarily when cartilage moves to bone), forms desme hexagonal structure of the nucleus membrane of the eye XIII type, XV type, XVII type, XVIII type having domains that penetrate the cell membrane.
- Vimentin is a medium-diameter filament protein that is characteristically expressed in mesenchymal cells such as fibroblasts and white blood cells. Vimentin filament assembly is controlled by phosphorylation by various protein kinases. It is known to be expressed transiently during development. Insulin-like growth factor-binding protein 7 (IGFBP7) binds to IGF-1 receptor and blocks activation of IGF-1 receptor by insulin-like growth factor. For this reason, the abundance of IGFBP7 is a protein that shows an inverse correlation with tumor progression.
- IGFBP7 Insulin-like growth factor-binding protein 7
- Fibronectin is a glycoprotein that forms an extracellular matrix, and a polypeptide having a molecular weight of about 250 kDa forms a dimer. It mainly promotes adhesion of fibroblasts, hepatocytes, and nerve cells. Integrin, a specific receptor on the cell membrane surface, is involved in cell adhesion, cell migration, phagocytosis, etc., as well as in tissue damage.
- Decorin is a small dermatan sulfate proteoglycan, bone proteoglycan II, PG-40, PG-II, PG-2, DS-PGII, a proteoglycan with a single chondroitin sulfate hybrid chain in the core protein of 38kDa (molecular weight 38,000) Yes, it is bound to collagen fibers. It is widely distributed in connective tissues of animals such as cartilage, bone, tendon, skin, sclera and aorta.
- Plasminogen activator inhibitor binds to and inhibits tissue plasminogen activator, which plays an important role in fibrin lysis. Most important is PAI-1, which is produced in the vascular endothelium and is also present in platelets. In addition, there is PAI-2 produced in the placenta and PAI-3 that blocks activated protein C (APC). An increase in blood concentration of PAI-1 causes a tendency to thrombosis, but it is a kind of acute phase protein, which is higher in the afternoon than in the morning and has a positive correlation with acylglycerol taken in the blood.
- Actin cytoplasmic 2 is a muscle contractile protein. Actin is considered to function mainly as actin filaments in cells. In muscle cells, actin filaments associate with type II myosin to form actomyosin bundles and contribute to muscle contraction. In non-muscle cells, including neurons, actin filaments are prominent filopodia, filamentous lamella lipodia (Lamellipodia), activated type II myosin It forms a variety of actin structures such as stress fibers consisting of actomyosin bundles associated with the.
- actin structural rearrangements are spatiotemporally controlled by intracellular signal transduction via Rho family low molecular weight G proteins, and are important in dynamic control of cell morphology such as cell movement and cell division. Take on. At the same time, it contributes to vesicle transport along actin filaments through binding to atypical myosin. In addition to this dynamic role, actin filaments accumulate directly under the cell membrane and form the lining structure of the cell cortex, as well as cadherin, which is a cell adhesion factor via ⁇ -catenin and vinculin. Combine to support cell-cell adhesion.
- Sulfhydryl oxidase 1 is a thiol oxidase using R′C (R) SH as a substrate.
- SPARC is a 30 kDa non-collagenous protein present in bone and dentin, and plays a central role in the function of dermis formation. Secreted from fibroblasts, enhances the synthesis of collagen and hyaluronic acid.
- Metalloproteinase inhibitors are endogenous inhibitors that control the activity of matrix metalloproteinases (MMPs).
- MMP matrix metalloproteinases
- TIMP-1 and 2 both bind to the active site of many MMPs and irreversibly inhibit their activity. In addition, these two TIMPs act directly on various cells and exhibit growth promoting activity.
- SCP2 refers to microbial cells or protein extracts from cells produced in large quantities using petroleum, natural gas, alcohol, molasses, agricultural products, etc. as fermentation raw materials.
- single cell protein it may be a product obtained by sterilizing and drying unicellular organisms rich in proteins such as yeast, bacteria, filamentous fungi and algae.
- the 72 kDa type IV collagenase is also called gelatinase, and among the gelatinases, the A enzyme is called 72 kDa type IV collagenase (MMP-2).
- MMP-9 The 95 kDa B enzyme is called MMP-9.
- MMP-2 has three repeats of type II fibronectin domain inserted in the catalytic domain, and belongs to the gelatinase group of MMPs together with MMP-9.
- MMP-2 is collagen I, IV, V, VII, X, XIV, gelatin (gelatin), elastin, laminin-1, laminin-5, myelin basic protein, MMP-1, MMP-9, Direct or indirect substrate specificity for MMP-13.
- Rho GTPase activating proteins are a group of G proteins that do not have a subunit structure with a molecular weight of 20,000 to 30,000 and constitute a superfamily. This superfamily is divided into five groups: Ras, Rho, Rab, Arf, and Ran.
- Rho GTPase activating protein is a protein belonging to Rho. Rho proteins regulate smooth muscle contraction, cytokinesis, cell motility, and cell morphology through reorganization of actin filaments.
- Bone marrow stromal cells are cells that exist in the bone marrow, can be easily collected by bone marrow puncture, and support hematopoiesis.
- the bone marrow includes cells roughly classified into two, blood cells and stromal cells that support blood cells, but bone marrow stromal cells are included in the latter.
- Blood cells proliferate in suspension when cultured, but bone marrow stromal cells grow by adhering to the walls.
- the shape is the same as mesenchymal cells, but takes a reticulated structure in the bone marrow. It can be cultured in the same way as normal fibroblasts. Originally, mesenchymal stromal cells differentiate into various cells.
- Bone marrow stromal cells are induced to differentiate into bone cells, chondrocytes, adipocytes, and skeletal muscle cells.
- a dental pulp cell is a kind of stem cell contained in a tooth nerve. The dental pulp cells are protected by a hard material called teeth, and since the teeth do not transmit ultraviolet rays or radiation, it is said that genes are not easily damaged.
- the immortalized deciduous dental stem cell is a cell obtained by immortalizing the dental pulp stem cell obtained from the deciduous tooth. Teeth are made of a hard material, physically protect the pulp, and are impervious to ultraviolet rays and radiation.
- Immortalized stem cells are prepared as follows. First, the deciduous deciduous teeth are disinfected with, for example, chlorohexidine, isodine solution or other disinfectant. Next, when using the animal's femur as the sole, for example, a syringe filled with PBS or the like is used to select a syringe needle with a thickness that fits tightly into the spinal cord of the animal's femur and extrude bone marrow cells. And take it out. In the case of porcine teeth or human fallen deciduous teeth, each crown is divided and the pulp tissue is collected with a dental reamer.
- porcine teeth or human fallen deciduous teeth each crown is divided and the pulp tissue is collected with a dental reamer.
- the harvested bone marrow mesenchymal cells or dental pulp tissue is converted into a basic medium such as Dulbecco's method containing 5-15% bovine serum (hereinafter sometimes referred to as “CS”) and 50-150 units / mL antibiotics. Suspend in Eagle medium (Dulbecco's Modified Eagle's Medium, hereinafter referred to as “DMEM”). Subsequently, the cells are treated with 1-5 mg / mL collagenase and 1-5 mg / mL dispase at 37 ° C. for 0.5-2 hours.
- CS bovine serum
- DMEM Dulbecco's Modified Eagle's Medium
- fetal bovine serum is added to the above-mentioned medium, for example, DMEM, and after enzyme treatment, centrifugation is performed for 3 to 10 minutes (3,000 to 7,000 rpm) to collect dental pulp cells. If necessary, cell sorting is performed using a cell strainer. The sorted cells are resuspended in, for example, 3 to 6 mL of the above basic medium, and seeded in an adherent cell culture dish having a diameter of 4 to 8 cm.
- the cells are cultured in a 5% CO 2 incubator at 37 ° C., for example, for about 2 weeks while changing the medium every 2 to 3 days. . During this period, 2-4 passages are performed. After confirming that the cells have become subconfluent, the culture medium is removed, and the cells are washed 1 to several times with PBS or the like. Instead of removing the culture medium and washing the cells, the adhesive dental pulp stem cells that formed colonies can also be recovered. Adherent dental pulp stem cells are detached from the dish by treatment with, for example, 0.025-0.1% trypsin and 0.3-1 mM EDTA for several minutes at 37 ° C., and the cells are then collected.
- a culture solution such as DMEM containing 10% FCS
- centrifugation is performed for 3 to 10 minutes (3,000 to 7,000 revolutions / minute) after enzyme treatment, and pulp cells are collected.
- cell sorting is performed using a cell strainer.
- the sorted cells are resuspended in, for example, 3 to 6 mL of the above basic medium, and seeded in an adherent cell culture dish having a diameter of 4 to 8 cm.
- a culture solution for example, DMEM containing 10% FCS is added, and the cells are cultured for a desired period in the same manner as described above, and the cells are washed 1 to several times with PBS or the like to obtain adherent cells.
- bone fluid (approximately 30-100 ⁇ L / femur) obtained from the medullary cavity of the rat's femur is replaced with approximately 5-15% fetal bovine serum (FBS), penicillin and streptomycin. It is preferable to select cells having desired characteristics by placing them in DMEM containing (Wako Pure Chemical Industries, Ltd.) and performing pre-culture for 2 to 4 generations at 37 ° C. in a 5% CO 2 incubator. For example, bone fluid (about 50 ⁇ L / femur) is placed in DMEM containing 10% FBS, the above-mentioned concentrations of penicillin and streptomycin, and precultured for 3 generations at 37 ° C. in a 5% CO 2 incubator. In the sorting step described later, cells having characteristics such as spindle shape and adhesiveness are selected.
- FBS fetal bovine serum
- the selected adherent cells are obtained.
- stem cells are seeded in an adherent cell culture dish and cultured under conditions of 5% CO 2 and 37 ° C.
- BMSCs obtained from the femur are used, only cells having characteristics such as spindle shape and adhesiveness are selected and used.
- the subculture is detached and collected from the culture vessel using trypsin and EDTA as described above.
- the sub-conflict refers to a state in which cells adhere to about 70% of the cell attachment surface in the culture vessel.
- the subculture is performed 1 to 8 times, and the selected cells are grown to the required number of cells, for example, about 1 ⁇ 10 7 cells / mL.
- the cells are collected and stored in liquid nitrogen. Cells collected from various donors may be stored in the form of dental pulp stem cell banks.
- the stem cells obtained as described above are initially cultured to obtain initialized cultured cells.
- HTERT, bmi-1, E6, and E7 are introduced into the initial cultured cells as follows.
- a plasmid for incorporating the above gene is prepared, and this is incorporated into a shuttle vector such as pSuttle2, and the above gene is cloned.
- E. coli is transformed with this shuttle vector, and kanamycin somatic transformants are selected.
- the plasmid DNA of the selected kanamycin somatic transformant is purified and the restriction enzyme site is analyzed to identify the recombinant.
- the expression cassette is then excised from the shuttle vector using restriction enzymes such as PI-Sce I and I-Cue I and ligated to an adenoviral vector such as Adeno-X viral DNA.
- the resulting ligation product is cleaved with SwaI and used to transform E. coli.
- hTERT is a gene of telomere repair enzyme
- bmi-1 is a gene of Bmi-1, which is one of the proteins constituting the polycomb complex.
- Bmi-1 is necessary for maintenance of hematopoietic stem cells, and has an effect that hematopoietic stem cells can be increased by enhancing the activity.
- E6 and E7 are the early genes of HPV-16 or HPV-18 DNA.
- Oct3 / 4 is a gene that activates transcription of the target gene in cooperation with Sox2.
- Klf4 Keruppel-type transcription factor 4 regulates genes involved in cell division and embryogenesis, and has been implicated as a tumor suppressor for digestive cancer.
- Sox2 belongs to the SRY-related HMG box gene family, and is a gene known to be involved in maintaining undifferentiated (pluripotent) functions.
- c-Myc is an oncogene and promotes both cell survival and death in tumors induced with c-Myc.
- p16INK4a is a gene that plays an important role in controlling the cell cycle of cancer cells.
- the recombinant adenovirus is then digested with Pac I and transfected into HEK293 cells. Recombinant adenovirus is propagated and collected to determine virus titer.
- the virus is purified according to a conventional method and infected with the target cell, SHED.
- the cell group after virus infection is stained with FITC according to a conventional method, and STRO-1-positive cells are detected using a flow cytometer.
- STRO-1 is considered as one of the markers of pluripotent mesenchymal stem cells in the bone marrow and serves as an indicator of cell immortalization.
- Bone marrow stromal cells, dental pulp cells, and immortalized deciduous dental stem cells derived from dental pulp can be obtained.
- Bone marrow stromal cells, dental pulp cells and immortalized deciduous dental pulp cells obtained as described above should be derived from rat, porcine or human deciduous teeth, and it is easy to obtain a source for obtaining these cells.
- these cells are preferably cultured at 37 ° C.
- the cell sorting step it is preferable to sort cells having spindle-shaped and spindle-type adhesive properties. Further, it is preferable to collect the culture supernatant from 44 to 52 hours after the start of the culture because the content of cells having a spindle shape and a spindle shape and adhesiveness is large. Moreover, it is more preferable to collect the culture supernatant 48 hours after the start of the culture because cells having higher adhesion can be obtained.
- the culture supernatant contains at least type I collagen (Col-I), fibronectin, decorin, vascular endothelial growth factor (VEGF), and bone sialoprotein (BSP) produced by the sorted cells.
- Col-I type I collagen
- VEGF vascular endothelial growth factor
- BSP bone sialoprotein
- IGF insulin-like growth factor binding protein 7
- follistatin related protein metalloproteinase inhibitor I
- tissue plasminogen activator inhibitor actin
- actin actin
- sulfhydryl oxidase I It further includes at least one protein selected from the army consisting of insulin-like growth factor (IGF) -1, stem cell growth factor (HGF), and TGF- ⁇ , further integrating the metal implant material with the bone Preferred because it is promoted.
- the culture supernatant obtained as described above is centrifuged and then subjected to ethanol precipitation to prepare a precipitate.
- unnecessary cells are removed by centrifugation at 1,000 to 2,000 rpm for 3 to 10 minutes, 2,500 to 3,500 rpm for 1 to 5 minutes, and 0 to 10 ° C.
- add approximately 8-12 volumes of ethanol to the supernatant incubate at -5-15 ° C for 30-90 minutes, and centrifuge at 2-6 ° C at 10,000-20,000 rpm for 10-20 minutes. Except for clearing, a precipitate is obtained. Thereafter, the precipitate obtained in the precipitate preparation step is freeze-dried.
- the product of the cell can be obtained.
- the obtained cell product is preferably stored at ⁇ 20 to ⁇ 40 ° C. from the viewpoint of maintaining activity.
- a highly functional implant is produced as follows. Specifically, (f) a cleaning step of cleaning the surface of the implant material with an organic solvent to obtain a cleaning implant material; and (g) the cleaning implant material in a calcification solution having a predetermined composition at a predetermined temperature. And (h) a treatment step in which the immersion implant material is treated with a solution containing a cell product at a predetermined concentration.
- the implant material is formed of any material selected from the group consisting of titanium, zirconia, hydroxyapatite, and ⁇ -TCP. It is preferable from the viewpoint of easiness. Among these, it is more preferable to use titanium (Ti) because it is easy to process with the stem cell culture supernatant and has high efficiency.
- acetone and 60 to 80% (v / v) ethanol as the organic solvent because the cleaning effect on the surface of the implant material is high.
- the reason why the ethanol concentration is 60 to 80% (v / v) is that if it is less than 60%, the cleaning power is weak, and if it exceeds 80%, no further cleaning effect can be obtained.
- the implant material cleaned as described above is immersed in a calcification solution having a predetermined composition for 3 to 6 hours.
- the composition of the first calcification solution is 100-150 mM NaCl, 2.5-3.5 mM CaCl 2 ⁇ H 2 O, 1.5-2.5 mM K 2 HPO 4 , 25-75 mM Tris-HCl (pH 7.2-7.6) Is preferable from the aspect of the efficiency of calcification, and 136.8 mM NaCl, 3.10 mM CaCl 2 ⁇ H 2 O, 1.86 mM K 2 HPO 4 , 50 mM Tris-HCl (pH 7.4) has high calcification efficiency. Is preferred.
- the immersion time is set to 3 to 6 hours because there is a problem that calcification is not sufficient if it is less than 3 hours, and no further effect is obtained even if it exceeds 6 hours.
- An immersion time of 4 hours is preferable because sufficient calcification is performed.
- the immersion is preferably performed at 36 to 38 ° C. in order to prepare in advance for immersion in a second calcification solution described later, and more preferably performed at 37 ° C.
- the implant material that has been soaked as described above is incubated with a second calcification solution containing a culture at a predetermined concentration for a predetermined time to attach Col-I, BSP, VEGF, and other growth factors.
- the second calcification solution may have a composition of 130 to 160 mM KNO 3 , 1 to 2 mM Ca (NO 3 ) 2 ⁇ 4H 2 O, 0.5 to 1.5 mM K 2 HPO 4 (pH 7.0 to 7.8). It is preferable because of its high protein attachment efficiency.
- the concentration of the aqueous solution is less than 5 mg / mL, there is a problem that the amount of the growth factor adhering is insufficient and the adhesion to the alveolar bone is weak. It is because it cannot be obtained. It is more preferable to treat with an aqueous solution having a concentration of 10 mg / mL since sufficient adhesion to the alveolar bone can be secured.
- a highly functional implant having at least Col-I, bone sialoprotein (BSP), and VEGF on its surface can be obtained.
- BSP bone sialoprotein
- VEGF vascular endothelial growth factor
- Rat BMSCs were obtained from the medullary cavity of rat femur. Bone marrow fluid (50 ⁇ L / femur) is collected and Dulbecco's modified MEM (DEMEM, containing 10% fetal bovine serum (FBS, Wako Pure Chemical Industries, Ltd.), penicillin and streptomycin (Wako Pure Chemical Industries, Ltd.) Sigma-Aldrich) and pre-cultured at 37 ° C. for 3 passages in a 5% CO 2 incubator. The medium was changed every 2 days. Only cells with characteristics such as spindle shape and adhesion were used.
- DEMEM Dulbecco's modified MEM
- CM preparation Cultured BMSCs were grown to 70-80% confluent, washed 3 times with warm phosphate buffered saline (PBS), and serum-free DMEM containing penicillin and streptomycin was added .
- PBS warm phosphate buffered saline
- DMEM serum-free DMEM containing penicillin and streptomycin was added .
- the culture supernatant after 48 hours (hereinafter sometimes referred to as “CM”) was collected, centrifuged at 1,500 rpm for 5 minutes, and then centrifuged at 3,000 rpm for 3 minutes to remove other cells.
- 5 mL of CM was mixed with 45 mL of 100% ethanol and incubated at ⁇ 20 ° C. for 1 hour. This mixture was centrifuged at 4 ° C. and 15,000 rpm for 15 minutes, and the supernatant was removed.
- CM precipitate was resuspended in cold 90% ethanol ( ⁇ 20 ° C.) and centrifuged at 4 ° C. and 15,000 rpm for 15 minutes. The final precipitate was frozen at ⁇ 80 ° C., lyophilized and stored at ⁇ 30 ° C. until use. Serum-free DMEM not contacted with cells was used as a control.
- CM-fixed Ti implant screw Ti implant screws (total length 5 mm, thread diameter 2 mm, and 1 mm pitch) were provided by Nishijima Medical Co., Ltd. These Ti implants were manufactured under the conditions obtained in previous studies.
- the surface of the Ti implant was treated with PBS alone, DMEM alone or CM, and each was treated with PBS treatment group (negative control group), DMEM treatment group (positive control group) and CM / DMEM treatment group (test group).
- PBS treatment group negative control group
- DMEM treatment group positive control group
- CM / DMEM treatment group test group
- the Ti implant was washed with acetone and 70% ethanol, and the first mineralized solution [50 mM Tris-HCl (pH 7.4) containing 136.8 mM NaCl, 3.10 mM CaCl 2 ⁇ H 2 O, 1.86 mM K 2 HPO 4 (Wako Pure Chemical Industries, Ltd.)) was immersed at 37 ° C. for 4 hours.
- the first mineralized solution [50 mM Tris-HCl (pH 7.4) containing 136.8 mM NaCl, 3.10 mM CaCl 2 ⁇ H 2 O, 1.86 mM K 2 HPO 4 (Wako Pure Chemical Industries, Ltd.)
- FIGS. 1 (A) to (F) show micrographs obtained by observing the surface of each Ti implant material in the second calcification solution immediately after the start of incubation and after the end with a scanning electron microscope (manufactured by JEOL Ltd.) are shown in FIGS. 1 (A) to (F). Shown in Figures 1 (A) to (C) were taken at 3,000 times, and (D) to (F) were taken at 15,000 times. (A) and (D) show typical topography when the surface of the Ti implant is mechanically polished. (C) and (E) show a snow scene-like microstructure. In (F), a snow scene-like microstructure and microspheres (microspheres) on the surface of the Ti implant were observed. Microspheres are indicated by arrows. The line segments shown in the figure are 10 ⁇ m for (A) to (C) and 2 ⁇ m for (D) to (F).
- the adherent rat BMSCs were incubated with 0.05% trypsin-EDTA (Sigma-Aldrich) for 10 minutes and detached from the Ti disk. This Ti disk was observed by SEM, and it was confirmed that BMCs of all rats were detached. The detached cells were calculated using a hemocytometer (Sunlead Glass (made)). The experiment was repeated three times, and statistical significance was analyzed by one-way analysis of variance (ANOVA) using the Scheff test at a significance level of 5% (p ⁇ 0.05). The results are shown in FIG. Significant differences were observed between the PBS treatment group and the DMEM treatment group, and between the PBS treatment group and the CM treatment group (*: p ⁇ 0.05, ANOVA test).
- the gel cut as described above was first washed and washed twice in 25 mM NH 4 HCO 3 containing 100 ⁇ L of 30% (v / v) acetonitrile for 20 minutes, and then CVE-3100 (Tokyo Rika) And dried with a machine).
- In-gel digestion of protein is 50 mM iodoacetamide (manufactured by Wako Pure Chemical Industries, Ltd.) / 100 mM NH 4 HCO 3 (pH 7.8) containing 20 ⁇ g / mL sequence grade trypsin (Promega).
- Peptides were extracted in 60% acetonitrile containing 0.1% TFA for 20 minutes at room temperature and peptide samples were dried in CVE-3100.
- PMF Peptide mass fingerprinting
- AMR Paradigm MS4-LCQ Advantage
- CM culture supernatant
- ALP alkaline phosphatase
- OCN osteocalcin
- OPN osteopontin
- BSP bone sialoprotein
- Col-I type I collagen
- VEGF A vascular epidermal growth factor A
- RNA analysis of rat BMSCs Rat BMSCs were cultured on Ti disks treated with PBS, DMEM or CM. The immobilization and culture methods are the same as those used for the cell adhesion analysis. BMSCs were cultured for 1 day, 7 days, 14 days. Total RNA from rat BMSCs cultured on each disk was performed using TRIZOL reagent (Invitrogen Life Technology) according to the manufacturer's protocol.
- cDNA from 1 ⁇ g total RNA, 10 ⁇ reaction buffer, 5 mM dNTP mix, 1 U / ⁇ L RNase inhibitor, 0.25 U / ⁇ L reverser enzyme (M-MLV reverse transcriptase, Invitrogen), and 0.125 ⁇ M random primer Synthesized in a 20 ⁇ L reaction solution containing (Takara Bio Inc.).
- CM labeling using QDs was performed according to the manufacturer's instructions. Briefly, Ti specimens treated with calcification solution were treated with 25 ⁇ L of 8 ⁇ M QDs, 1 mg / mL CM, 1 mL of 10 mM borate buffer (pH 7.4), and 5.7 ⁇ L of 10 mg / mL N-ethyl-N.
- A, B, and C respectively show images of the Ti implant before the start of the test.
- A1 shows an image 1 day after the start of the test
- A7 shows an image after 7 days
- A14 shows an image after 14 days
- A28 shows an image after 28 days.
- B and C For Ti implants treated with PBS, no fluorescence was detected around it throughout the observation period. In contrast, a trend was detected around the Ti implant treated with DMEM or CM. From the above, it was found that localization of biomolecules occurred in Ti implants treated with DMEM or CM.
- E. coli competent cells Supercharge EZ10 Electrocompetent Cells, product code 636756), Swa I (product code 1111A, Smi I is equivalent), Xho I (product code 1094A), T4 DNA Ligase (product) Code 2011A), NucleoBond Xtra Midi (product code 740410.10 / .50 / .100), and NucleoSpin Plasmid (product code 740588 10/50/250) were all purchased from Takara Bio Inc. Pac I was purchased from New England Biolabs.
- Buffer 1 25 mM Tris-HCl (pH 8.0) containing 10 mM EDTA and 50 mM glucose (stored at 4 ° C. after autoclaving)
- Buffer 2 0.2M NaOH containing 1% SDS (prepared immediately before use, sealed, and stored at room temperature)
- Buffer 3 5M KOAc (stored at 4 ° C after autoclaving)
- Buffer 4 10 mM Tris-HCl (pH 8.0) containing 1 mM EDTA, 20 ⁇ g / mL RNase (add RNase immediately before use and store at ⁇ 20 ° C.)
- HEK293 cells (ATCC # CRL1573) transformed with human type 5 adenovirus were used.
- HEK293 cells were cultured in complete medium.
- the composition of the complete medium was DMEM (basic medium) supplemented with 100 unit / mL penicillin G sodium, 100 ⁇ g / mL streptomycin, 4 mM L-glutamine and 10% FBS.
- Penicillin G sodium solution was prepared at 10,000 units / mL
- streptomycin sulfate solution was prepared at 10,000 ⁇ g / mL and stored as a stock solution.
- 60 mm plate, 100 mm plate, 6-well plate, T75 and T175 flasks were used.
- Trypsin-EDTA (product code CC-5012) was purchased from Takara Bio Inc. Phosphate buffered saline (without PBS, Ca2 + and Mg2 + ) and Dulbecco's phosphate buffered saline (containing DPBS, Ca2 + and Mg2 + ) were prepared. Further, a 0.33% neutral red staining solution and a 0.4% trypan blue staining solution were used.
- X-Gal (5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside [25 mg / mL]) dimethylformamide (DMF) solution was stored at ⁇ 20 ° C. in the dark. Luminescent ⁇ -gal Detection Kit II (product code 631712) was used.
- trypsin reaction was stopped by adding 10 mL complete medium and gently suspended. Viable count was performed, and 10 5 cells were transferred to a 100 mm plate containing 10 mL of the culture solution and spread uniformly.
- a recombinant adenovirus containing lacZ was constructed according to the attached protocol.
- the target cell, SHED was infected and assayed for ⁇ -galactosidase expression to confirm that the vector was constructed.
- rpShuttle2 Vector Before construction of recombinant pShuttle2 Vector (hereinafter referred to as “rpShuttle2 Vector”), DH5 ⁇ E. coli was transformed with pShuttle2 Vector and pShuttle2-lacZ Vector included in the kit. . A transformant was selected on an LB agar plate (hereinafter referred to as “LB / Kan”) containing 50 ⁇ g / mL kanamycin, and the cells taken from a single colony were streaked to a new LB / Kan. Incubate overnight at ° C.
- LB / Kan LB agar plate
- hTERT, bmi-1, E6, and E7 were cloned into pShuttle2 by the following procedure.
- the pShuttle2 Vector was cleaved with restriction enzymes suitable for these genes.
- pShuttle2 Vector Information Packet (PT3416-5) attached to the above kit, a multicloning site matching the DNA to be inserted was determined.
- the above plasmid treated with the restriction enzyme was purified by treatment with alkaline phosphatase.
- a target DNA fragment was prepared and purified according to a conventional method.
- the vector digested with the restriction enzyme and the gene fragment were ligated, and DH5 ⁇ cells (competent cells) were transformed with the ligation product.
- a part of the above competent cells was taken and transformed with the control vector pShuttle2-lacZ Vector included in the kit to serve as a positive control.
- the mixed solution containing transformed E. coli was inoculated on an LB / Kan agar plate, and kanamycin resistant (Kanr) transformants (colony) were selected. Five to ten Kan resistant clones were selected and inoculated into a small amount of liquid medium for amplification. After confirming that these clones had rpShuttle2 Vector, they were incubated overnight. Thereafter, the constructed plasmid DNA was purified by a conventional method using a commercially available silica adsorption column.
- rpShuttle2 plasmid DNA Recombinant pShuttle2 plasmid DNA
- rpShuttle2 plasmid DNA was directly transfected into target cells, and Western blotting was performed to preliminarily check the expression of the target protein.
- Phenol chloroform: isoamyl alcohol extraction
- a centrifuge tube add 70 ⁇ L of 1 ⁇ TE Buffer (pH 8.0) and 100 ⁇ L of PCI mixture to the remainder of the double digestion solution (25 ⁇ L), Vortex thoroughly. Subsequently, it was centrifuged at 14,000 rpm for 5 minutes at 4 ° C. using a microcentrifuge, and the aqueous layer was transferred to a clean 1.5 mL microcentrifuge tube. To this, 400 ⁇ L of 95% ethanol, 25 ⁇ L of 10M ammonium acetate, and 1 ⁇ L of glycogen (20 mg / mL) were added, and vortexed well.
- the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the supernatant was removed by aspiration to obtain a pellet.
- 300 ⁇ L of 70% ethanol was added and centrifuged at 14,000 rpm for 2 minutes at room temperature. The supernatant was carefully aspirated off and the pellet was air dried at room temperature for approximately 15 minutes. After the pellet was dried, it was dissolved in 10 ⁇ L of sterile 1 ⁇ TE buffer (pH 8.0) and stored at ⁇ 20 ° C. until use.
- Adeno-X plasmid DNA was purified according to the mini-scale method described later.
- the cell suspension was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the clear supernatant was transferred to a clean 1.5 mL centrifuge tube.
- 450 ⁇ L of a PCI mixed solution was added, mixed by inversion and stirred. Thereafter, the mixture was centrifuged at 14,000 rpm for 5 minutes at 4 ° C., and the aqueous layer was transferred to a clean 1.5 mL microcentrifuge tube.
- Each culture plate was transfected with 10 ⁇ L of Pac I-digested Adeno-X plasmid DNA, and Adeno-X DNA was introduced into HEK293 cells according to a standard transfection method (CalPhos Mammalian Transfection Kit product code 631312). From the day after transfection, it was confirmed whether CPE (cytopathic effect) occurred. One week later, the cells adhering to the bottom and sides of the culture plate were gently agitated to release them. The resulting cell suspension was transferred to a 15 mL sterilized conical centrifuge tube and centrifuged at 1,500 ⁇ g for 5 minutes at room temperature.
- the resulting precipitate was suspended in 500 ⁇ L of sterile PBS.
- the freeze-thaw operation of freezing in dry ice / ethanol and thawing in a constant temperature bath at 37 ° C. was repeated three times to obtain a lysate in which cells were sufficiently thawed.
- the suspension was lightly centrifuged to remove the suspended matter, and the supernatant was transferred to another sterilized tube and used immediately.
- the portion not used immediately was stored at -20 ° C.
- 250 ⁇ L of the lysate was added to cultured cells on a 60 mm plate, and the culture was continued.
- the titer of adenovirus was measured using the anti-Hexon antibody contained in Adeno-X Rapid Titer Kit (product code 631028) according to the instruction manual (PT3651-1) of this kit.
- CPE was confirmed by culturing at 37 ° C. in the presence of 5% CO 2 for 3 to 4 days.
- a free cell suspension was prepared in the same manner as above and transferred to a 15 mL sterilized conical centrifuge tube. Freezing and thawing operations similar to the above were performed to thaw the cells.
- a titer of 10 7 PFU / mL was obtained using the Adeno-X Rapid Titer Kit (product code 631028). Western blotting was performed to confirm that the packaged adenovirus genome has a functional copy of the transcription unit specific for the gene of interest.
- Adenovirus infection to target cells (7-1) Infection to target cells 6-well plates were inoculated with 1 ⁇ 10 6 SHEDs 24 hours before infection. The day after inoculation, the medium was removed and 1.0 mL of medium containing virus was added to the center of each plate. This solution was spread evenly over the monolayer formed by SHED. The cells were cultured at 37 ° C. in the presence of 5% CO 2 for 4 hours to infect the virus with SHED. Then, a fresh medium was added and further cultured at 37 ° C. in the presence of 5% CO 2 . Transgene expression was analyzed over time from 24 to 48 hours after infection.
- Example 3 Preparation of immortalized deciduous dental stem cells
- deciduous deciduous dental pulp cells Decided deciduous teeth obtained from a 10-year-old healthy boy were used. After this deciduous deciduous tooth was sterilized with an isodine solution, the dental crown was cut horizontally using a dental diamond point, and the pulp tissue was collected using a dental reamer. The obtained dental pulp tissue was digested in a solution of 3 mg / mL type I collagenase and 4 mg / mL dispase at 37 ° C. for 1 hour. The solution was then filtered using a 70 mm cell strainer (Falcon).
- the cells separated by filtration were resuspended in 4 mL of the above medium and seeded in an adherent cell culture dish having a diameter of 6 cm.
- DMEM containing 10% FCS was added to the dish and cultured for about 2 weeks in an incubator adjusted to 5% CO 2 and 37 ° C.
- the adherent cells (dental pulp stem cells) that formed colonies were treated with 0.05% trypsin / EDTA for 5 minutes at 37 ° C., and the cells detached from the dish were collected.
- adherent cells selected as described above are seeded in an adherent cell culture dish (collagen-coated dish), and then primary cultured in an incubator adjusted to 5% CO 2 and 37 ° C. It was.
- the cells become sub-confluent (about 70% of the surface of the culture container) or confluent by macroscopic observation, the cells are detached from the culture container by treatment with 0.05% trypsin / EDTA for 5 minutes at 37 ° C. And recovered.
- the cells thus obtained were seeded again in a dish containing the above medium, and subculture was performed several times to grow to about 1 ⁇ 10 7 cells / mL.
- the resulting cells were stored in liquid nitrogen. Thereafter, primary cultured cells were subcultured at a concentration of about 1 ⁇ 10 4 cells / cm 2 using the above medium. Cells passaged 1-3 times were used for experiments.
- Human BMMSCs (Bone Marrow Mesenchymal stem cells) were purchased from Lonza and cultured according to the manufacturer's instructions.
- SHED human fallen deciduous dental pulp stem cells
- SHED was fixed with 3% paraformaldehyde, then rinsed twice with PBS and treated with 100 mM glycine for 20 minutes. These cells were then permeabilized with 0.2% Triton-X (Sigma-Aldrich) for 30 minutes and then incubated in a mixture of 5% donkey serum and 0.5% bovine serum albumin for 20 minutes. Next, the cells were incubated with the primary antibody mouse anti-human STRO-1 antibody (1: 100, manufactured by R & D) for 1 hour, and the secondary antibody goat anti-mouse immunoglobulin M-FITC antibody (1: 500, Incubated with Southern Biotech) for 30 minutes and mounted using Vector Shield DAPI (Vector Laboratories Inc). Thereafter, ⁇ -MEM supplemented with 15% FBS was placed in a 6-well plate, and the sorted cells were seeded for clone preparation. Approximately 300 colonies from the expanded cells were pooled for testing.
- SHED-T 1 ⁇ 10 6 pieces of SHED were seeded on a collagen-coated dish of 100 mm ⁇ , and DMEM supplemented with 10% FBS was added and cultured until sub-confluent.
- infected cells were selected by culturing for 10 days in the above medium supplemented with puromycin (1 pg / mL), and 500-600 resistant clones were pooled. Every 3-4 days, about 0.5 ⁇ 10 5 SHEDs were seeded in a 100 mm ⁇ culture dish and subcultured.
- SHED-T 1 ⁇ 10 6 pieces of SHED was introduced was referred to as SHED-T, and the SHED into which the gene was not introduced was referred to as SHED-C.
- FIG. 5 shows the doubling state of the number of individuals of SHED-T (SHED into which gene was introduced).
- the vertical axis represents the number of individual doublings (number of cell divisions), and the horizontal axis represents time (culture days).
- the state in which SHED in culture does not divide for one month was used as a criterion for cell aging.
- SHED-C stopped growing after about 30 times, and entered the aging or growth stopping stage.
- SHED-T exceeded 250 PD and proliferated after 800 days.
- SHED-C the proportion of STRO-1 positive cells was 27% in PD20 and decreased to 15% in PD30 (FIGS. 6 (A) and (B)).
- SHED-T the proportion of STRO-1 positive cells was 46% for PD20 and 41% for PD40, respectively (FIGS. 6C and 6D).
- FIG. 8 shows changes in the amount of new bone between SHED-T and SHED-C at each individual doubling number (doubling time).
- ** represents p ⁇ 0.05
- *** represents p ⁇ 0.01.
- the amount of new bone was calculated
- SHED-C the amount of new bone decreased as the number of individuals increased, and with PD20, it decreased to about 1/5 of PD0.
- SHED-T the amount of new bone hardly changed until PD20, and it was shown that in PD20, SHED-T formed more than five times the bone of SHED-C.
- Example 4 Implants and surgical procedures Ti implants (titanium fixtures) were inserted into the femur as previously described (reference number 40). Rats were anesthetized with a combination of inhalation of diethyl ether vapor (3 mL / chamber) and intraperitoneal administration of pentobarbital (20 mg / kg). A 10 mm incision was made beyond the distal femur and the bone was exposed.
- a unicortical implant floor was formed 7 mm from the distal end of the femur at a rotational speed of 1500 rpm or less using a dental round bar (diameter 1.5 mm). Implants treated with CM, DMEM or PBS were inserted and embedded in cortical bone. Thereafter, the soft tissues were returned to their normal positions and sutured with 3-0 bicyclyl (registered trademark) SH-1 (Ethicon).
- FIG. 10 (A) for cancellous bone
- FIG. 10 (B) for cortical bone.
- the bone graft contact rate was significantly different in cancellous bone between the negative control group and the other two groups at 7 and 14 days after transplantation.
- cortical bone a significant difference was observed between the test group and the negative control group 1 day after transplantation (ANOVA test, *: p ⁇ 0.05, **: p ⁇ 0.01).
- a high BIC value in the test group indicated that integration with the bone was promoted.
- Example 5 Production of high-performance human implant (1) Material and method The implant used was a titanium implant (length 13 mm, diameter 3.75 mm, or length 11 mm, diameter 3.75 mm) manufactured by Astra. (2) Preparation of growth factor-containing culture supernatant Using the stem cell culture supernatant obtained in Example 1, a growth factor-containing solution was prepared and treated as follows.
- the culture supernatant was put into a culture flask, a titanium implant material was added thereto, the lid was tightened tightly and shaken sufficiently. Sonicated with a sonicator for 1 minute. Next, the mixture was allowed to stand for 5 minutes, and again sonicated for 1 minute under the same conditions. After standing for 5 minutes, it was washed twice with pure water. As described above, a titanium implant coated with a growth factor contained in the culture supernatant was obtained. In place of the culture supernatant, the same treatment was carried out using only DMEM to prepare an untreated titanium implant material.
- Example 6 Example of transplantation of high-functional implant (1) Patients, etc.
- the implant prepared in Example 5 was transplanted to the maxillary edentulous jaw of 8 men aged 41 to 68 years. None of these patients had diabetes, hypertension or other underlying diseases affecting bone metabolism. Also, there was no heavy drinking and no smoking habits.
- the site where the distance from the maxillary sinus floor was 15 mm or more in the maxillary molar region was designated as the implantation site. Eight implants treated with growth factor (treated group) were placed in the maxillary molar region on one side of the patient, and eight implants not treated with growth factor (untreated group) were placed on the opposite maxillary molar of the same patient Embedded in the department.
- Example 7 Analysis of protein attached to culture supernatant and high-functional implant surface (1) Material and method Using the protein in the culture supernatant of stem cell obtained in Example 1, LC / MS / MS ( Identification was performed using MS4 HPLC System (Michrom BioResources) and LCQ Advantage mass spectrometry system (Thermo Scientific). The measurement conditions were as follows.
- LC MS4 HPLC System (Michrom BioResources) Column: Magic C18AQ (Michrom BioResources, 0.1mm (id) x 50cm) Eluent: Gradient solution A (2% acetonitrile-98% water (containing 0.1% formic acid)) and solution B (90% acetonitrile-10% water (containing 0.1% formic acid) (0 min, 95% A: 5 % B ⁇ 45 min, 0% A: 100% B). Flow rate: 1 ⁇ L / min MS1: LCQ Advantage mass spectrometry system (Thermo Scientific) MS2: LCQ Advantage mass spectrometry system (Thermo Scientific)
- the protein adhering to the implant is extracted by liquid chromatography in the order of 10% EDTA, 4M guanidine and 80% acetonitrile, and each buffer is collected at a flow rate of 2 mL / min. Prepared to 2 ⁇ g / mL. The amount of protein was measured by the biuret method. The culture supernatant was ethanol-precipitated using 100% ethanol and 90% ethanol and then lyophilized to prepare a protein amount of 2 ⁇ g / mL. The amount of protein was measured by the Bradford method. The analysis results are shown in Table 9.
- the stem cell culture supernatant obtained in Example 1 contained a lot of proteins related to the formation of the cell structure. Further, from the large proportion of adherent cells after culturing the mesenchymal stem cells obtained as described above, collagen ⁇ -1 (I) chain, collagen ⁇ -2 (I) chain, fibronectin, and decorin However, it is thought that it plays an important role in the adhesion between the implant and the alveolar bone.
- Example 8 Effect of culture supernatant on cell adhesion and effect of cryopreservation
- Material The culture supernatant of stem cells obtained in Example 1 was used as a sample, and PBS was used as a negative control.
- (2) Effect on cell adhesion 10 mL of bone marrow fluid was collected from the canine bone marrow stromal cells (age 18-25 months, body weight 15-25 kg) from the iliac bone of a beagle dog on a 15 mm diameter pure titanium plate, 10% FBS and 1.5-3 ⁇ 10 5 cells / well pre-cultured at 37 ° C.
- the culture was performed at 37 ° C. using DMEM containing 10% FBS, penicillin (50 to 150 U / mL) and streptomycin (50 to 150 ⁇ g / mL).
- DMEM fetal bovine serum
- penicillin 50 to 150 U / mL
- streptomycin 50 to 150 ⁇ g / mL
- a pure titanium plate with a diameter of 15 mm was irradiated with atmospheric pressure plasma (MPS-01K01C, manufactured by Kagurita Manufacturing Co., Ltd.) at a distance of 10 mm from the tip of the plasma flame. And soaked at 37 ° C. for 24 hours.
- the number of adherent cells at 1 hour and 24 hours after the start of the culture was determined by detaching adherent cells with trypsin-EDTA and counting floating cells on a hemocytometer.
- the results are shown in FIG. In FIG. 12, N-PBS is cultured in PBS without plasma treatment, P-PBS is plasma treated and cultured in
- N-PBS did not show a large increase in the number of adherent cells even after 24 hours, but P-PBS showed a large increase.
- the number of adherent cells increased after 24 hours.
- There was a significant difference in the number of adherent cells after 24 hours between the N-PBS group and the P-CM group (p ⁇ 0.01).
- a significant difference was also observed between the P-PBS group and the P-CM group (p ⁇ 0.05).
- the activity when stored for 1 month tended to decrease compared with the case stored for 1 week, but no significant difference was observed.
- a significant difference was observed between the case where it was stored at ⁇ 80 ° C. for 2 weeks and the case where it was stored at ⁇ 15 ° C. for 1 month (p ⁇ 0.05).
- a significant difference was observed between the case of storage at ⁇ 80 ° C. for 2 weeks and the case of storage at 4 ° C. for 1 month (p ⁇ 0.05).
- the present invention is useful in the dental and medical fields.
- Sequence number 1 Forward primer for ALP Sequence number 2: Reverse primer for ALP Sequence number 3: Forward primer for OCN Sequence number 4: Reverse primer for OCN Sequence number 5: Forward primer for OPN Sequence number 6: Reverse for OPN Primer SEQ ID NO: 7: Forward primer for BSP SEQ ID NO: 8: Reverse primer for BSP SEQ ID NO: 9: Forward primer for Collagen 1 SEQ ID NO: 10: Reverse primer for Collagen 1 SEQ ID NO: 11: Forward primer for GAPDH SEQ ID NO: 12: GAPDH reverse primer SEQ ID NO: 13: Collagen ⁇ -1 (I) chain precursor SEQ ID NO: 14: Collagen ⁇ -1 (II) chain precursor SEQ ID NO: 15: Collagen ⁇ -1 (XXVII) Chain precursor SEQ ID NO: 16: Collagen ⁇ - 2 (I) Strand precursor SEQ ID NO: 17: Fibronectin SEQ ID NO 18: fibronectin SEQ ID NO: 19: decorin SEQ ID NO: 20: decorin SEQ
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
Abstract
Description
本来、欠損した歯等に十分な機能を発揮させるためにインプラントを安定化させることが必要であるから、インプラントは歯槽骨と一体化することが望ましい。このため、こうしたインプラント材料として、バイオガラスやリン酸カルシウムセラミックス(すなわち、ヒドロキシアパタイト及びβ-リン酸三カルシウム)その他の生物活性材料及び金属材料が使用されてきた。
また、金属インプラント材料表面の処理は、まず、金属インプラント表面を活性化する前処理を行い、その後に骨形成試薬で処理する、又は成長因子を適用するという手順で行われるため、操作が煩雑であった。さらに、金属インプラント材表面に成長因子を適用する場合には、その表面に固定した成長因子の保持される期間が問題となる。金属インプラント材の表面に保持される期間が、骨と金属インプラント材料とが一体化するのに必要な時間と比べて短ければ、十分な一体化が望めないからである。
すなわち、本発明の第1の態様は、5~15%の血清、50~150U/mLのペニシリン及び50~150μg/mLのストレプトマイシンを含有する培養液中に、5×103~5×104個/mLの骨髄間質細胞又は不死化乳歯幹細胞を加えて、34~37.5℃、5%CO2存在下に、予備培養を行う予備培養工程と;所定の形状と接着性とを有する前記細胞を選別する細胞選別工程と;前記選別工程で選別された細胞を予備培養と同じ条件で培養し、培養開始後40~56時間の培養上清を集める培養上清収集工程と;を備える、細胞産生物の調製方法である。
また、前記細胞選別工程における所定の形状は、スピンドル形状かつ紡錘型であることが好ましい。前記培養上清は、培養開始後44~52時間で集めることが好ましく、培養開始後48時間で集めることがさらに好ましい。
また、上記調製方法は、遠心及びエタノール沈殿処理を行って沈殿物を調製する沈殿物調整工程と、前記沈殿物調製工程で得られた沈殿物を凍結乾燥させる凍結乾燥工程とをさらに備えることが好ましい。
さらに、前記所定の温度が36~38℃であり、浸漬時間が4時間であることが好ましい。前記所定の細胞産生物は、上記の細胞産生物の5~20mg/mLの水溶液であることが好ましく、約10mg/mLであることがさらに好ましい。
上記インプラントは、少なくとも、少なくとも、I型コラーゲン(Col-I)、フィブロネクチン、及びデコリンを表面に保有することが好ましく、インスリン様成長因子結合タンパク質7(IGF-binding protein 7)、フォリスタチン関連タンパク質、メタロプロテイナーゼインヒビターI、組織プラスミノーゲンアクチベーターインヒビター、アクチン、及びスルフヒドリルオキシダーゼIからなる群から選ばれる少なくとも1以上のタンパク質をさらに表面に有することがさらに好ましい。
さらにまた、短期間で骨との一体化ができる、高機能インプラント材を得ることができる。
本発明の調製方法は、(a)5~15%の血清、50~150U/mLのペニシリン及び50~150μg/mLのストレプトマイシンを含有する培養液中に、5×103~5×104個/mLの骨髄間質細胞又は不死化乳歯幹細胞を加えて、34~37.5℃、5%CO2存在下に、予備培養を行う予備培養工程と;(b)所定の形状と接着性とを有する前記細胞を選別する細胞選別工程と;(c)前記選別工程で得られた細胞を予備培養と同じ条件で培養し、培養開始40~56時間後の培養上清を集める培養上清収集工程と;を備えている。
培地に添加可能な成分としては、上記の血清のほか、血清代替物(Knockout serum replacement(KSR)など)、ウシ血清アルブミン(BSA)、ペニシリン、ストレプトマイシン、ゲンタマイシンその他の抗生物質、ビタミンK、葉酸その他の各種ビタミン類、カルシウム、マグネシウムその他の各種ミネラル、アルギニン、トリプトファンその他のアミノ酸等を挙げることができる。
また、本発明は、(d)遠心及びエタノール沈殿処理を行って沈殿物を調製する沈殿物調整工程と;(e)前記沈殿物調製工程で得られた沈殿物を凍結乾燥させる凍結乾燥工程と;をさらに備える方法とすることができる。
前記骨髄間質細胞は、ラットの大腿骨、ブタ下顎及び歯、及びヒト乳歯からなる群から選ばれるいずれかの細胞に由来するものであることが、一定の種類の細胞成長因子を安定して産生できる細胞を確実に入手できることから好ましい。
成長因子は、生体内における種々の細胞学的プロセス、生理学的プロセスの調節に関与していることが知られており、標的細胞表面にある受容体タンパク質(以下、単に「受容体」又は「レセプター」ということがある。)に特異的に結合し、シグナル伝達を行う。
β型変異増殖因子TGF-βは腎臓、骨髄、血小板などほぼすべての細胞で産生され、5種類のサブタイプ(β1~β5)が存在する。TGF-β1~β3は、骨基質中に不活性型として蓄積されており、骨吸収の際に破骨細胞が放出する酸によって活性化される。TGF-βは、骨芽細胞の増殖及びコラーゲン等の間葉細胞の合成・増殖を促進するが、上皮細胞の増殖や破骨細胞に対しては抑制的に作用する。
上記の成長因子は、それらの構造及び進化の面から関連するいくつかのファミリーに分類される。これらのファミリーとしては、TGF-β、骨形成タンパク質(bone morphogenic protein:BMP)、ニューロトロフィン(神経栄養因子)、線維芽細胞増殖因子(FGF)等を挙げることができる。上記神経栄養因子には、NGF、BDNF、NT3等が含まれる。成長因子は現在、医療でも盛んに用いられている。
コラーゲンタンパク質ファミリーは、以下のように分類される。
1)特異的な、67nmの周期構造横紋構造を有する線維を形成する分子群(I型、III型、V型(主として軟骨以外の組織))、II型、XI型(軟骨組織)
3)網目状の会合体を形成している分子群(主として基底膜の骨格を形成するIV型コラーゲン)、細胞外の微細繊維を形成するVI型、皮膚等の表皮基底細胞からの基底板を突き抜けて存在するアンカリングフィブリルを形成するVII型
4)ヘキサゴナル格子を形成するX型(軟骨が骨へと移行する時期に暫定的に存在する)、目の核膜のデスメの六角構造を形成し、血管その他の組織にも存在する)、さらに細胞膜を貫通するドメインを有するXIII型、XV型、XVII型、XVIII型
インスリン様増殖因子結合タンパク質7(insulin-like growth factor-binding protein 7:IGFBP7)はIGF-1受容体に結合し、インスリン様増殖因子によるIGF-1受容体の活性化を遮断する。このため、IGFBP7の存在量は腫瘍進行と逆相関を示すタンパク質である。
SPARCは、骨と象牙質に存在する30kDaの非コラーゲン性タンパク質であり、真皮の形成を機能に中心的な役割を果たす。線維芽細胞から分泌され、コラーゲンとヒアルロン酸の合成を高める。
72kDa IV型コラゲナーゼはゼラチナーゼともいい、ゼラチナーゼのうち、A酵素を72kDa IV型コラゲナーゼ(MMP-2)と呼ぶ。95kDaのB酵素は、MMP-9と呼ばれる。MMP-2は、触媒ドメインに挿入されたII型ファイブロネクチンドメインの3つのリピートを有しており、MMP-9と共にMMPsのゼラチナーゼグループに属する。MMP-2はコラーゲンI, IV, V, VII, X, XIV, ゲラチン(gelatin), エラスチン、ラミニン-1、ラミニン-5、ミエリン塩基性タンパク質(myelin basic protein)、MMP-1, MMP-9, MMP-13に対して、直接あるいは間接的な基質特異性を示す。
Rho GTPase活性化タンパク質は、分子量2~3万のサブユニット構造を有していない一群のGタンパク質で、スーパーファミリーを構成している。このスーパーファミリーは、Ras, Rho, Rab, Arf, Ranの5つのグループに分類される。Rho GTPase活性化タンパク質は、このうちのRhoに属するタンパク質である。Rhoタンパク質は、アクチンフィラメントの再編成を介して、平滑筋の収縮や細胞質分裂、細胞運動、細胞形態を制御している。
歯髄細胞とは、歯の神経に含まれる幹細胞の一種である。歯髄細胞は、歯という硬質の素材に保護されており、歯は紫外線や放射線を通さないために、遺伝子も傷つきにくいといわれている。
採取した骨髄間葉細胞又は歯髄組織を、基本培地、例えば、5~15%ウシ血清(以下、「CS」ということがある。)及び50~150ユニット/mLの抗生物質を含有するダルベッコ変法イーグル培地(Dulbecco's Modified Eagle's Medium, 以下、「DMEM」という。)に懸濁する。ついで、1~5mg/mLのコラゲナーゼ及び1~5mg/mLのディスパーゼを用いて、37℃で、0.5~2時間処理する。
次いで、培養液、例えば、10%FCSを含有するDMEMを添加して、上記と同様に所望の期間培養し、PBS等で細胞を1~数回洗浄して接着性細胞を得る。
例えば、骨液(約50μL/大腿骨)を、10%FBS、上述した濃度のペニシリン及びストレプトマイシンを含むDMEMに入れ、5%CO2インキュベータ中にて、37℃で、3代予備培養を行い、後述する選別工程において、スピンドル形状及び接着性等の特徴を有する細胞を選択する。
大腿骨から得たBMSCsを使用した場合には、スピンドル形状及び接着性等の特徴を有する細胞のみを選択して使用する。
ここで、サブコンフレントとは、培養容器中の細胞付着面の約70%に細胞が付着した状態をいう。例えば、継代培養を1~8回行い、選別された細胞を、必要な細胞数、例えば約1×107個/mLまで増殖させる。以上のように培養した後に、細胞を回収して液体窒素中にて保存する。様々なドナーから回収した細胞を歯髄幹細胞バンクの形態で保存することにしてもよい。
ここで、hTERTはテロメア修復酵素の遺伝子であり、bmi-1はポリコーム複合体を構成するたんぱく質の1つであるBmi-1の遺伝子である。ここで、Bmi-1は造血幹細胞の維持に必要であり、活性増強により造血幹細胞を増やすことができるという作用を有する。
Sox2はSRY-related HMG box遺伝子ファミリーに属しており、機能の未分化性(多能性)維持に関与することが知られる遺伝子である。c-Mycは発癌遺伝子であり、c-Mycで誘導された腫瘍内で細胞の生存と死の両方を促進する遺伝子である。p16INK4aはがん細胞のcell cycleをcontrolするのに重要な役割を果たす遺伝子である。
ウイルス感染後の細胞群を、常法に従ってFITCで染色し、フローサイトメーターを用いて、STRO-1陽性細胞を検出する。ここで、STRO-1は、骨髄における多分化能を有する間葉系幹細胞のマーカーの1つとして考えられており、細胞の不死化の指標となる。
以上のようにして得られる骨髄間質細胞、歯髄細胞及び不死化乳歯歯髄細胞は、ラット、ブタ又はヒト乳歯由来のものを使用することが、これらの細胞を得るためのソースを入手しやすいこと、及び安定して上述した成長因子を産生する細胞を得られることから好ましい。そして、(a)の予備培養工程では、これらの細胞を、37℃培養することが好ましい。
次いで、上記のようにして得られた凍結乾燥品を使用して、以下のようにして高機能インプラントを製造する。具体的には、(f)インプラント材の表面を有機溶媒で洗浄し、洗浄インプラント材とする洗浄工程と;(g)前記洗浄インプラント材を、所定の組成を有する石灰化溶液中に所定の温度で3~6時間浸漬し、浸漬インプラント材とする浸漬工程と;(h)前記浸漬インプラント材を所定の濃度の細胞産生物を含有する溶液で処理する処理工程と;を備える方法によって作成する。
ここで、浸漬時間を3~6時間とするのは、3時間未満では石灰化が十分でないという問題があり、6時間を越えてもそれ以上の効果が得られないからである。浸漬時間を4時間とすることが、十分な石灰化が行われるために好ましい。
上記のように浸漬処理を行ったインプラント材を、所定の濃度の培養物を含有する第2石灰化溶液で所定の時間インキュベーション処理することにより、Col-I、BSP、VEGFその他の成長因子を付着させる。上記第2石灰化溶液は、130~160 mMKNO3, 1~2mM Ca(NO3)2・4H2O, 0.5~1.5mM K2HPO4(pH 7.0~7.8)の組成とすることが、これらのタンパク質の付着効率が高いことから好ましい。
ここで、水溶液の濃度が5mg/mL未満では付着する成長因子の量が不十分で歯槽骨との接着性が弱いという問題があり、一方、20mg/mLを越えてもそれ以上高い接着性が得られないからである。10mg/mLの濃度の水溶液で処理することが、歯槽骨との十分な接着が確保できることから、さらに好ましい。
(実施例1)
(1)材料と方法
(1-1)動物
6週齢の雌のSDラット(n = 15、体重200-230g)を、日本SLC(株)より購入した。全ての実験は、名古屋大学医学部の実験ガイドラインに従って行った。これらの動物は、12時間の明暗サイクル下に、室温にて飼育した。飼料及び水は自由に摂取させた。
ラットのBMSCsを、ラットの大腿骨の髄腔から得た。骨髄液(50μL/大腿骨)を集めて、10%ウシ胎児血清(FBS、和光純薬工業(株))、ペニシリン及びストレプトマイシン(和光純薬工業(株))を含むダルベッコ変法MEM(DEMEM、シグマ-アルドリッチ社製)中にて、5%CO2インキュベータ中にて、37℃で3代予備培養した。2日ごとに培地を交換した。スピンドル形状及び接着性等の特徴を有する細胞のみを使用した。
培養したBMSCを70~80%コンフレントになるまで増殖させ、暖めたリン酸緩衝生理食塩水(PBS)で3回洗浄し、ペニシリン及びストレプトマイシンを含む無血清DMEMを加えた。48時間後の培養上清(以下、「CM」ということがある。)を集めて1,500 rpmで5分間遠心し、その後、3,000rpmで3分間遠心して他の細胞を除去した。5mLのCMを45mLの100%エタノールと混合し、-20℃にて1時間インキュベートした。この混合物を、4℃、15,000rpmにて15分間遠心し、上清を除いた。CMの沈殿物を冷90%エタノール(-20℃)に再度懸濁し、4℃、15,000rpmにて15分間遠心した。最終沈殿物を-80℃にて凍結させて凍結乾燥させ、-30℃で使用まで保存した。細胞と接触させていない無血清DMEMを対照として使用した。
Ti インプラントスクリュー(全長5mm、スレッド径2mm、及び1mm ピッチ)は、西島メディカル(株))より提供を受けた。これらのTiインプラントは、先の研究で得られた条件で製造された。
Tiインプラントの表面は、PBSのみ、DMEMのみ又はCMで処理し、それぞれ、PBS処理群(陰性対照群)、DMEM処理群(陽性対照群)及びCM/DMEM処理群(試験群)とした。
各処理群は、以下のようにして調製した。
まず、Tiインプラントをアセトンと70%エタノールで洗浄し、第1石灰化溶液[136.8mM NaCl, 3.10mM CaCl2・H2O, 1.86mM K2HPO4を含有する50mM Tris-HCl(pH 7.4)(和光純薬工業(株)製))中で、37℃にて、4時間浸漬した。
上記3種類の石灰化溶液3mL中に、洗浄済の各Tiインプラント材5本を浸漬し、37℃にて3日間、インキュベートした。インキュベーション終了後、各Tiインプラント材を取り出した。
(A)及び(D)は、Tiインプラントの表面を機械研磨したときの典型的なトポグラフィーを示した。(C)及び(E)は雪景色様の微細構造を示した。(F)では、Tiインプラント表面の雪景色様の微細構造及び微小球(ミクロスフェア)が観察された。微小球を矢印で示した。図中に示した線分は、(A)~(C)が10μm、(D)~(F)が2μmである。
Tiディスク(10×10mm;(株)オーファ製)を、Tiインプラント上への固定と同様の手法によって、PBS、DMEM、又はCMのいずれかで処理した。ラットのBMSCs(1.0×106個)を上記のように処理したTiディスク上に播種し(N=3)、10%FBS及び1%ペニシリン‐ストレプトマイシン含有DMEMを用いて、37℃にて、5%CO2存在下に24時間培養した。
PBS処理群及びDMEM処理群の間、及びPBS処理群及びCM処理群との間には、それぞれ有意差が見られた(*:p<0.05, ANOVA検定)。
以上より、PBSで表面を処理したTiインプラントは、図1(A)及び(D)に示すような機械研磨の典型的なトポグラフィーを示した。DMEMを固定化したTiインプラントは、雪景色様の微細構造を広く、不規則にディスプレイしていた(図1(B)及び(E))。CMでコートしたTiインプラントの表面は、雪景色様の微細構造上にミクロスフェアをディスプレイしていた(図1(C)及び(F)の矢印参照)。これらの結果は、CM又はDMEMの固定化成分により、インプラント表面のトポグラフィーが変化することを示唆した。
上記で得たCM/DMEM処理群のTiインプラント材の表面から、80%アセトニトリルを用いてタンパク質を剥離させた。剥離させたタンパク質は、凍結乾燥を行って粉末化した。粉末化したタンパク質1mgを100μLの泳動用サンプルバッファーで希釈し、希釈したバッファー10μLを、12%アクリルアミドゲルのゲルを使用したゲル電気泳動に供した。泳動後、CBB(コマジーブリリアントブルー)溶液、又はSilver Stain Kit(Therimo社製)を用いてそれぞれ染色を行なった。染色後、メスを用いてゲルを切り出した。
検索パラメータは、1 missed trypsin cleavageのトレランス、質量トレランス6100 ppm及びメチオニン残基の酸化を許容するように設定した。クエリーが、含有される4以上のペプチドとマッチし、Mascot search engineによって生成された統計的に有意なMowse(分子量サーチ;molecular weight search)スコアと一致する質量を有するときに、同定されたタンパク質を承認した。
フォワードプライマー GCTGTGAAGGGCTTCTTGTC・・・配列番号1
リバースプライマー CGCCTATCAGCTAATGCACA・・・配列番号2
フォワードプライマー TGAGGACCCTCTCTCTGCTC・・・配列番号3
リバースプライマー GAGCTCACACACCTCCCTGT・・・配列番号4
フォワードプライマー AGGTCCTCATCTGTGGCATC・・・配列番号5
リバースプライマー AGACTGGCAGTGGTTTGCTT・・・配列番号6
フォワードプライマー TTCTCGAGAAAAATTTCCA・・・配列番号7
リバースプライマー TCACTGGTGGTAGTAATAAT・・・配列番号8
フォワードプライマー CGATGCCATTTTCTCCCTTA・・・配列番号9
リバースプライマー CTCTGGTACCGCTGGAGAAG・・・配列番号10
フォワードプライマー ATGACTCTACCCACGGCAAG・・・配列番号11
リバースプライマー TTCAGCTCTGGGATGACCTT・・・配列番号12
ラットBMSCsを、PBS、DMEM又はCMで処理したTiディスク上で培養した。固定化及び培養方法は、細胞接着分析を行ったのと同じ方法である。BMSCsを、1日、7日、14日間培養した。各ディスク上で培養したラットBMSCsからの総RNAを、TRIZOL試薬(インビトロジェン ライフテクノロジー社製)を用いて、製造元のプロトコルにしたがって行った。cDNAを、1μgの総RNAから、10x反応バッファー、5mM dNTP混合物、1U/μLのRNaseインヒビター、0.25U/μLの逆転者酵素(M-MLV逆転写酵素、インビトロジェン社)、及び0.125μMのランダムプライマー(タカラバイオ(株))を含む20μLの反応液中で合成した。
ラットのグリセルアルデヒド-3-ホスフェート・デヒドロゲナーゼ(GAPDH)プライマーを、内部標準として使用した。in vitro遺伝子発現分析において、移植された培養細胞中のGAPDHに対するmRNAの発現レベル(%)を、Scion Image picture-imaging software (Scion社製)を使用して測定した。合成されたcDNAを、表1に示す特異的プライマーを用いた次のPCR増幅用の鋳型として使用した。すべての実験は3回繰り返し、データを有意差レベル5%で、Scheffe検定を用いて、一元配置分散分析(ANOVA)により解析した。
結果をOCN,OPN及びCol Iの遺伝子の発現パターン(図3(A)~(C)参照)及びそれを定量化したグラフ(図3(D)~(F)参照)として図3に示した。
QDs (インビトロジェン・モレキュラー・プローブス社製)を用いたCMのラベリングは、製造元の指示書に従って行った。簡単に言えば、石灰化溶液で処理したTi検体 を、25μLの8μM QDs、1mg/mLのCM、1mLの10mMのホウ酸バッファー(pH 7.4)、及び5.7μLの10mg/mL N-エチル-N’-ジメチルアミノプロピル-カルボジイミド(架橋試薬;シグマ‐アルドリッチ社製)の混合物に添加し、室温でそっと1時間攪拌した。血清不添加のDMEM又はPBSのQDラベリングを、対照として使用した。結果を図4に示す。
PBSで処理したTiインプラントでは、観察期間中を通して、その周囲に蛍光は検出されなかった。これに対し、DMEM又はCMで処理したTiインプラントでは、その周囲に傾向が検出された。
以上から、DMEM又はCMで処理したTiインプラントでは生体分子の局在化が起きていることが判明した。
(1)プラスミド抽出用試薬
(1-1)試薬等
カナマイシン(Kan)、アンピシリン(Amp)、LB液体培地及びLB寒天培地、グリコーゲン、アガロース、滅菌水、酢酸アンモニウム、酢酸ナトリウム、ドデシル硫酸ナトリウム及びRNase Aを使用した。50mg/mLのカナマイシン(Kan)及びアンピシリン(Amp)を調製し、ストック溶液として-20℃で保存した。グリコーゲンは20mg/mLに調製した。10mg/mLのRNase Aを調製し-20℃で保存した。10M(飽和)酢酸アンモニウム(NH4OAc)、3Mの酢酸ナトリウム(NaOAc;pH5.2)を調製した。
大腸菌コンピテントセル(Supercharge EZ10 Electrocompetent Cells、製品コード 636756)、Swa I(製品コード 1111A、Smi Iが同等品)、Xho I(製品コード 1094A)、T4 DNA Ligase(製品コード 2011A)、NucleoBond Xtra Midi(製品コード 740410.10/.50/.100)、NucleoSpin Plasmid(製品コード 740588 10/50/250)は、いずれもタカラバイオ(株)より購入した。Pac IはNew England Biolabs社より購入した。
1×TE Buffer(1mMのEDTAを含む10mM Tris-HCl[pH8.0])、100mM Tris-HCl(pH8.0)で飽和したフェノール:クロロホルム:イソアミルアルコール(25:24:1、以下、「PCI混液」という。)を調製した。エタノールは、100%及び70%で使用した。ミニスケールでの組換えで使用するpAdeno-X プラスミドDNAの精製用に、以下のバッファー1~4を調製した。
バッファー2:1%SDSを含む0.2M NaOH(使用直前に用時調製、密封し、室温保存)
バッファー3:5M KOAc(オートクレーブ後、4℃で保存)
バッファー4:1mMのEDTA、20μg/mLのRNaseを含む10mMのTris-HCl(pH8.0)(使用直前にRNaseを添加し、-20℃で保存)
ヒト5型アデノウイルスで形質転換したヒトHEK293細胞(ATCC #CRL1573)を使用した。HEK293細胞は完全培地で培養した。完全培地の組成は、100 unit/mLのペニシリンGナトリウムと100μg/mLのストレプトマイシン、4mMのL-グルタミン及び10%FBSを添加したDMEM(基本培地)とした。ペニシリンGナトリウム溶液は10,000 units/mL、硫酸ストレプトマイシン溶液は10,000μg/mLで調製し、ストック溶液として保存した。
培養には、60mmプレート、100mmプレート、6-ウェルプレート、T75及びT175フラスコを使用した。
β-galアッセイには、X-Gal(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside [25mg/mL])ジメチルホルムアミド(DMF)溶液は-20℃で遮光保存した。Luminescent β-gal Detection Kit II(製品コード 631712)を使用した。
(3-1)lacZ を含む組換えアデノウイルス(pAdeno-X-lacZ)の構築
10mLの上述した完全培地に、解凍後、DMSOを除去したHEK293細胞を再懸濁し、全量を100mmの培養プレートに移した。HEK293細胞が付着した後に培養液を除去し、細胞を滅菌PBSで1度洗浄し、1mLのトリプシン-EDTA溶液を加えて約2分間処理した。
pShuttle2-lacZ(Adeno-X Expression System 1に含まれている陽性対照ベクター)とキットに含まれているAdeno-X Viral DNA(PI-Sce I及びI-Ceu I digested)とを使用し、キットに添付されているプロトコルに従って、lacZを含む組換えアデノウイルスを構築した。標的細胞であるSHEDに感染させ、β-ガラクトシダーゼの発現をアッセイし、ベクターが構築されていることを確認した。
組換えpShuttle2 Vector(以下、「rpShuttle2 Vector」という。)の構築前に、キットに含まれているpShuttle2 Vector及びpShuttle2-lacZ VectorでDH5α大腸菌を形質転換した。50μg/mLのカナマイシンを含有するLB寒天プレート(以下、「LB/Kan」という。)上で形質転換体を選択し、単一コロニーからとった菌体を新しいLB/Kanに画線し、37℃で一晩インキュベートした。
次いで、hTERT、bmi-1、E6、E7を、pShuttle2へ以下の手順でクローニングした。これらの遺伝子に適した制限酵素でpShuttle2 Vectorを切断した。
次いで、上記のキットに添付されているpShuttle2 Vector Information Packet(PT3416-5)を参照し、挿入するDNAに合致するマルチクローニングサイトを決定した。制限酵素処理済みの上記プラスミドをアルカリホスファターゼで処理して精製した。
形質転換した大腸菌を含む混合液を、LB/Kan寒天プレートに接種し、カナマイシン耐性(Kanr)の形質転換体(コロニー)を選択した。5~10個のKan耐性クローンを選択し、少量の液体培地に接種して増幅した。これらのクローンがrpShuttle2 Vectorを有していることを確認した後に、一晩インキュベートした。その後、市販のシリカ吸着カラムを用いて、常法に従い、構築されたプラスミドDNAを精製した。
組換えpShuttle2プラスミドDNA(以下、「rpShuttle2プラスミドDNA」という。)をターゲット細胞に直接にトランスフェクトし、ウエスタンブロットを行って目的タンパク質の発現を予備的にチェックした。
上記のようにして作製したrpShuttle2プラスミドDNAから、導入した遺伝子の発現カセットをPI-Sce I及びI-Ceu Iで切り出した。キットに添付されたプロトコルに記載されたin vitroライゲーション法に従って、切り出した発現カセットをAdeno-X Viral DNAに組み込んだ。rpShuttle2プラスミドDNAのPI-Sce I/I-Ceu I二重消化液を30μL調製し、下記の表1に記載した試薬を1.5mLの滅菌済みマイクロ遠心チューブに入れて混合した。
遠心チューブに、上述した二重消化液の残り(25μL)に、70μLの1×TE Buffer(pH8.0)と100μLのPCI混液とを添加し、ボルテックスで十分に撹拌した。次いで、微量遠心機を用いて、4℃にて14,000rpmで5分間遠心し、水層を清浄な1.5mLのマイクロ遠心チューブに移した。ここに、400μLの95%エタノール、25μLの10Mの酢酸アンモニウム、及び1μLのグリコーゲン(20mg/mL)を添加し、ボルテックスで十分に撹拌した。
(4-1)Adeno-X ウイルスゲノムへの発現カセットのサブクローニング
下記の表4に示す試薬を、順番通りに1.5mLの滅菌済マイクロ遠心チューブに入れ、穏やかに混和し、軽く遠心した後に、16℃にて一晩インキュベートした。
4℃にて5分間、14,000rpmで遠心し、上清を吸引により除去してペレットを得た。以下のエタノール沈殿操作は、上記(3-4)と同様に行った。
ペレットが乾燥した後に、これを15μLの滅菌脱イオン水に溶解した。
(4-2)組換えAdeno-X プラスミドDNAのSwa I消化
下記表5に示す消化液を調製し、遠心チューブに入れた各サンプルに加えて、2時間、25℃にて、インキュベートした。
電気的にコンピテントにした大腸菌を、Supercharge EZ10 Electrocompetent Cell(製品コード 636756)を使用して、上記(4-2)で得たSwa I消化産物で形質転換した。
形質転換混合液を、LB培地にアンピシリン(終濃度100μg/mL)を加えた寒天プレート(以下、「LB/Amp寒天プレート」という。)に接種し、37℃で一晩インキュベートして、アンピシリン耐性(Ampr)形質転換体を選択した。約106個のコロニーを得た。得られたコロニーを、製品に付属のAdeno-X System PCR Screening Primer Setでチェックした。
対数増殖にある培養液5mLを、14,000rpmで30秒間遠心し、上清を除去した。ペレットを再度10,000rpmで1分間遠心し、マイクロピペットを用いて、上清を除去した。
ここに、150μLの上記バッファー1を加えて穏やかにピペッティングし、再懸濁した。この細胞懸濁液に、150μLのバッファー2を添加し、穏やかに転倒混和し、氷上に5分間放置した。冷却した細胞懸濁液に、150μLのバッファー3を加えて、再度転倒混和し、氷上に5分間放置した。
この細胞懸濁液を、4℃にて14,000rpmで5分間遠心し、透明な上清を清浄な1.5mLの遠心チューブに移した。この上清に、450μLのPCI混液を添加し、転倒混和して撹拌した。その後、4℃にて14,000rpmで5分間遠心し、水層を清浄な1.5mLのマイクロ遠心チューブに移した。
(5)得られたrAdeno-X プラスミドDNAの制限酵素部位解析
PI-Sce I及びI-Ceu Iを用いて解析を行った。下記の表6に示す試薬を、1.5mLの滅菌済みマイクロ遠心チューブに入れ、30μLのPI-Sce I/I-Ceu I二重消化反応液を加えて、十分に撹拌し、軽く回転させて内容物を集めた。
(6)組換えアデノウイルスの産生
(6-1)HEK293細胞トランスフェクト用rAdeno-X プラスミドDNAの調製
下記表7に示す試薬等を、1.5mLの滅菌済み遠心チューブに入れて混合し、微量遠心機で軽く遠心した。その後、37℃にて2時間、インキュベートし、rAdeno-X プラスミドDNAのPac I制限酵素処理を行った。
以下のエタノール沈殿の操作は、上記(3-4)と同様に操作を行い、ペレットの溶解液は、使用まで-20℃にて保存した。
(6-2)Pac I消化Adeno-X プラスミドDNAのHEK293細胞へのトランスフェクション
上記プラスミドDNAのトランスフェクションの24時間前に、60mmの培養プレートあたりの細胞数が1~2×106(およそ100 cells/mm2)になるよう、HEK293細胞を接種し、37℃、5%CO2存在下でインキュベートした。
1週間後に、培養プレートの底面や側面に付着している細胞を穏やかに撹拌して遊離させた。得られた細胞懸濁液を15mLの滅菌済みの円錐遠心チューブに移し、室温にて5分間、1,500×gで遠心した。
60mmプレートの培養細胞に250μLの上記ライセートを加えて、培養を続けた。なお、Adeno-X Rapid Titer Kit(製品コード 631028)に含まれる抗Hexon 抗体を用いて、このキットの取扱説明書(PT3651-1)に従い、アデノウイルスの力価を測定した。
この力価測定を始める約24時間前に、HEK293細胞をT75フラスコに接種し、37℃、5%CO2存在下で一夜培養し、50~70%コンフルエントになっていることを確認した。
翌日、ウイルスを含む新しい培地と交換し、MOI=10で感染させた。37℃、5%CO2存在下で90分間培養した後にフラスコを取り出し、10mLの培地を加えた。
ウェスタンブロッティングを行い、パッケージングされたアデノウイルスゲノムが、目的遺伝子に特異的な転写単位のコピーを、機能する形で持っているかを確認した。
(7-1)標的細胞への感染
感染の24時間前に6-ウェルプレートに1×106個のSHEDを接種した。接種の翌日に培地を取り除き、ウイルスを含む1.0mLの培地を各プレートの中心に添加した。この溶液をSHEDが形成した単層全体に均一に広げた。
37℃、5%CO2存在下で4時間培養し、ウイルスをSHEDに感染させた。次いで、新鮮な培地を添加し、さらに、37℃、5%CO2存在下で培養した。感染24時間後~48時間後にかけて導入遺伝子の発現を経時的に解析した。
(7-2)感染細胞のβ--ガラクトシダーゼ発現の解析
Adeno-X-lacZを感染させた接着性細胞におけるβ--ガラクトシダーゼの発現は、Luminescent β-galDetection Kit II(製品コード 631712、クロンテック社)を使用してアッセイした。
(1)脱落乳歯歯髄細胞の調製
10歳の健常男児から得られた脱落乳歯を使用した。この脱落乳歯をイソジン溶液で消毒した後、歯科用ダイヤモンドポイントを用いて、歯冠を水平方向に切断し、歯科用リーマーを用いて歯髄組織を回収した。得られた歯髄組織を、3mg/mLのI型コラゲナーゼ及び4mg/mLのディスパーゼの溶液中で37℃にて1時間消化した。ついで、この溶液を70mmの細胞ストレーナ(Falcon社製)を用いて濾過した。
その後、一次培養細胞を上記の培地を用いて約1×104細胞/cm2濃度で継代培養した。1~3回継代した細胞を実験に用いた。ヒトBMMSCs(Bone Marrow Mesenchymal stem cells、骨髄間葉系幹細胞)はロンザ社から購入し、メーカーの取扱説明書に従って培養した。
ブロモデオキシウリジンBrdU染色キットのメーカー(Invitrogen社製)の取扱説明書に従いBrdUを12時間取り込ませ、SHEDの増殖速度を評価した(各群についてn=3)。実験は5回繰り返した。1元配置分散分析後に、Tukey-Kramer検定を行い、統計的有意差を評価した。
次に、細胞を一次抗体のマウス抗ヒトSTRO-1抗体(1:100、R&D社製)と一緒に1時間インキュベートし、二次抗体のヤギ抗マウス免疫グロブリンM-FITC抗体(1:500、Southern Biotech社製)と一緒に30分間インキュベートし、ベクタシールドDAPI(Vector Laboratories Inc)を用いてマウントした。
その後、15%FBSを添加したα-MEMを6ウェルプレートに入れ、ソートした細胞をクローン作製用に播種した。増殖した細胞の中から約300コロニーを試験用にプールした。
上述したように、bmi-1, E6, E7及びhTERTの4つの遺伝子をアデノウイルスベクターに組み込み、これらの遺伝子産物を発現するウイルスベクターを作製した。対照として、これらの遺伝子を組み込んでいない対照ベクターを作製した。
SHED-T(遺伝子導入をしたSHED)の個体数の倍加状態を、図5に示した。図中、縦軸は個体数倍化回数(細胞分裂回数)、横軸は時間(培養日数)である。また、培養中のSHEDが1ヶ月間分裂しない状態を、細胞の老化の判断基準とした。
SHED-Cは30回程で増殖が停止し、老化又は増殖停止段階に入った。これに対し、SHED-Tは250PDを超え、800日経過後も増殖した。
単一細胞の懸濁液を得るため、接着性の単層細胞をトリプシン/EDTAで消化した。2x105個の細胞に抗STRO-1モノクローナル抗体(1:100)を加えて放置し、FACSCaliburフローサイトメーター(Becton Dickinson社)を使用して分析した。対応するアイソタイプが同一の対照抗体と比較し、99%以上の割合で蛍光レベルが高い場合に発現が陽性とした。SHED-T及びSHED-Cともに、初期及び後期の継代細胞を固定し、FITC結合STRO-1抗体で染色した。その後、フローサイトメトリーで分析した。試験はそれぞれ二回行なった。SHED-CではSTRO-1陽性細胞の割合がPD20で27%であり、PD30では15%まで減少した(図6(A)及び(B))。SHED-TではSTRO-1陽性細胞の割合が、それぞれPD20で46%、PD40で41%であった(図6(C)及び(D))。
PD0、PD10及びPD20におけるSHED-C及びSHED-Tの分化能を、新生骨量の形成能及び組織染色で調べた。
まず、2.0 x 106個のSHED-C又はSHED-Tを、40mgのヒドロキシアパタイト/三カルシウムリン酸(HA/TCP)セラミック粉末(オリンパス工業(株)製)に混合し、10週齢の免疫無防備状態マウス(NIH-bgnu-xid, 雌、Harlan Sprague Dawley社製)の背側表面の皮下に移植した。
移植8週間後に移植物を回収し、4%ホルマリンで固定して脱灰した後、パラフィン包埋するため10%EDTAを含むPBS溶液でバッファリングした。一部は、プラスチック包埋するために70%エタノール溶液中に保存した。
新生骨量=新生骨面積/視野面積×100
図8に示されるように、SHED-Cでは個体数倍加回数が増えるについて新生骨量が減少し、PD20ではPD0の約1/5まで低下した。これに対し、SHED-Tでは、PD20まで新生骨量はほとんど変動がなく、PD20では、SHED-TはSHED-Cの5倍以上の骨を形成したことが示された。
SHED-C及びSHED-T細胞を、免疫無防備状態マウスの皮下組織に、1×106個移植した。移植後、30日以上観察を行ったが、この期間中、上記の細胞を移植したいずれのマウスにおいても、腫瘍は形成されなかった。また、SHED-T細胞では、40~200PDの培養細胞のすべてのクローンの形態に変化はなかった。
以上より、SHED-Tには、癌化活性はないことが示された。
SEHD-Tは、260PDを超えても分化能力を保ったまま増殖する能力を有していることが示されたが、SHED-Cは、分化能力を有するものの30PD以下で老化した。
以上から、SHED-Tは不死化細胞となっており、活性の高いSHED培養上清の大量生産に適することが示された。
(5)CM固定Tiインプラントスクリューの調製
CM固定Tiインプラントスクリューの調製、細胞接着分析、走査型電子顕微鏡(SEM)によるTiインプラント表面の変化の観察、LC/MS/MSによるTiインプラント表面上のタンパクの同定及びインビトロにおけるSHEDのRNA分析は、上述した実施例1と同様に行った。
(1)インプラント及び外科的手順
Tiインプラント(チタンフィクスチャー)を、既に記載したように(文献番号40)、大腿骨中に挿入した。ラットを、ジエチルエーテル蒸気(3mL/チャンバー)の吸入と、ペントバルビタール(20 mg/kg)の腹腔内投与の組み合わせとにより麻酔した。10mmの切開口を遠位大腿骨を超えて形成し、この骨をむき出しにした。
固定化したQD-修飾CMを有するTiインプラントをトラックし、イメージングシステム(IVIS spectrum, Xenogen社製)を用いて可視化した。ラットを、移植後1日目、7日目、14日目、及び28日目にそれぞれ屠殺し、埋め込んだTiインプラントを有する大腿骨を取り出した。取り出したラットの大腿骨中のTiインプラントと会合した(associated with)QD-ラベルを、イメージングによって検出した。
各ラット及び取り出した大腿骨を、以下の条件でイメージングした:
視野: 13×13cm
暴露時間: 1秒
f-ストップ: 1
バインディング: 8
励起フィルター: 605nm
放射フィルター: 655nm又は検体の高さ: 0.01cm
暴露時間: 2秒
f-ストップ: 1
バインディング: 8,
励起フィルター: 605nm,
放射フィルター: 655nm,
大腿骨インプラントの除去トルク(Ncm)を、インプラント設置後1日、7日、14日及び28日の時点で、実験群ごとに深麻酔下に測定した(各時点においてN=5)。除去トルクを、トルクゲージATG 3 CN(登録商標、測定レンジ:0.1‐3 Ncm;Tohnichi, Tokyo, Japan)及びBTG 15 CN-S(登録商標、測定レンジ:2-15 Ncm;(株)東日製作所製)を用いて測定した。データを有意差レベル5%で、Scheffe検定を用いて、一元配置分析により解析した。
結果を図9に示す。陰性対照群(PBS処理群)と陽性対照群(DMEM処理群)との間では、1日後、及び7日後で有意差が見られたが、14日後には有意差は見られなかった。試験群(CM処理群)では、全ての測定時点で対照群よりも高い値を示し、14日後まで有意差が見られた(*はp<0.05を示す。)。
除去トルク測定後、ラット(各群ともN=5)を深麻酔下に屠殺し、大腿骨インプラントを取り出した。得られた試料を、Technovit 7100(応研商事(株))中に埋め込んだ。各ブロックをインプラントの長軸方向に沿って移動させ、50μm厚の切片を作成し、トルイジンブルーを用いて、通常の方法で染色した。
切片の顕微鏡画像をモニター上に表示してコンピュータ入力し、イメージ分析用ソフトウェア(VMS-50 VideoPro、イノテック(株)製)を用いて分析した。骨接触率は、下記の式によって求めた:
骨接触率(%)=直接移植‐骨接触/ペリインプラント長。
データを有意差レベル5%で、Scheffe検定を用いて、一元配置分析で解析した。結果を図10に示す。
試験群でBICの値が高いことから、骨との一体化が促進されていることが示された。
(1)材料と方法
インプラントは、アストラ社製のチタンインプラント(長さ13mm、直径3.75mm、又は長さ11mm、直径3.75mm)を使用した。
(2)成長因子含有培養上清の調製
実施例1で得た幹細胞の培養上清を用いて成長因子含有溶液を調製し、以下のように処理を行った。
(1)患者等
41歳~68歳の男性8名の上顎無歯顎に、実施例5で作製したインプラントを移植した。これらの患者には、糖尿病、高血圧その他の骨代謝に影響を与える基礎疾患はなかった。また、飲酒量が多いということもなく、喫煙習慣もなかった。
ある患者では、上顎臼歯部で、上顎洞底との距離が15mm以上残存している部位を埋入部位とした。成長因子で処理したインプラント(処理群)8本を患者の一方側の上顎臼歯部に埋入し、成長因子で処理していないインプラント(無処理群)8本を、同一患者の反対側上顎臼歯部に埋入した。
上記16本のインプラントを埋入した直後(埋入時)、6カ月後、及び12ヶ月後の時点で、オステルモニター(Ostell Mentor, Ostell AB, Grothenburug, Sweden)を用いて、ISQ(Implant Stability Quotient)の変動によって評価した。
ISQ値は、インプラント周囲の骨の高さや質、骨とインプラントの結合力によって変化し、1から100の間の数値で表示される。一般的に、成功したインプラントはISQが65±5の場合に多いといわれている。計測結果を図11に、また、評価を下記表8に示した。図11に示すように、設置時のISQは、対照群及びSHED-CM処理群ともにこの範囲内であった。ISQ値は、いずれの群においても経時的に上昇したが、6月経過時点でSHED-CM処理群が有意に高くなっていた(p<0.05)。この傾向は、12月経過でも同様であった。
(1)材料と方法
実施例1で得た幹細胞の培養上清中のタンパク質を使用し、LC/MS/MS(MS4 HPLC System (Michrom BioResources社製)とLCQ Advantage mass spectrometry system (Thermo Scientific社製)で同定した。
測定条件は、下記の通りとした。
カラム:Magic C18AQ(Michrom BioResources社製、0.1mm(i.d.)x50cm)
溶離液:溶液A(2% アセトニトリル-98% 水(0.1% 蟻酸含有))、溶液B(90% アセトニトリル-10% 水(0.1%蟻酸含有)をグラジエントさせた(0分, 95% A:5% B→45分, 0% A:100% B)。
流速:1μL/分
MS1:LCQ Advantage mass spectrometry system (Thermo Scientific社製)
MS2:LCQ Advantage mass spectrometry system (Thermo Scientific社製)
培養上清は、100%エタノール、90%エタノールを用いてエタノール沈殿をさせた後に凍結乾燥し、タンパク量が2μg/mLになるように調製した。タンパク量は、ブラッドフォード法にて測定した。
分析結果を表9に示す。
(1)材料
実施例1で得た幹細胞の培養上清を試料とし、陰性対照としてPBSを使用した。
(2)細胞の接着性に対する影響
直径15mm純チタン板に、イヌ骨髄間質細胞(年齢18-25ヶ月、体重15-25kgのビーグル犬の腸骨より骨髄液を10mL採取し、10%FBS及び50~150U/mLのペニシリン、50~150μg/mLのストレプトマイシンを含むDMEM培地を用いて、5%CO2インキュベータ中にて、37℃で3代予備培養したもの)を1.5~3x105個/ウェルで播種(n=3)し、培養上清の有無による細胞の接着性の影響、及びプラズマ処理の影響を調べた。
N-PBS群とP-CM群では、24時間後の接着細胞数に有意差が見られた(p<0.01)。また、P-PBS群とP-CM群との間にも、有意差が見られた(p<0.05)。
また、24時間後における細胞の付着状態を、DAPIとファロイジンとを用いて蛍光染色し、250倍で、蛍光顕微鏡(励起波長:358nm(DAPI), 560nm(ファロイジン)、測定波長:465nm(DAPI), 575nm(ファロイジン)、A1+(Nikon社製)で観察した。
結果を図13に示す。図13に示すように、細胞の増殖状況は、N-CM群及びP-CM群で、明らかに多くなっていた。
上記の培養上清を、1mLずつプラスチック製のネジ口チューブ(容量2mL、コーニング社製)に分注し、それぞれ、4℃、-15℃、及び-80℃で1週間、2週間及び1ヶ月保存した。
この影響を、ブロモウリジンアッセイで確認した。アッセイキットとして、BrdUラベリング&ディテクションキットII(ロシュ アプライドサイエンス社製)を使用し、添付された使用説明書に従ってアッセイを行った。
実施例1と同様にして得た間葉系幹細胞を、1x106個/ウェルで96ウェルプレートに播種した。上記のように保存した培養上清を100μL/ウェルで添加し、5%CO2インキュベータ中にて、37℃で24時間培養し、この幹細胞の増殖を観察し、増殖率を求めた。結果を図14に示す。
以上から、培養上清の保存期間は、-80℃で凍結保存した場合には1ヶ月、-15℃の場合には1ヶ月、4℃の場合には2週間と考えられる。
配列番号2:ALP用リバースプライマー
配列番号3:OCN用フォーワードプライマー
配列番号4:OCN用リバースプライマー
配列番号5:OPN用フォーワードプライマー
配列番号6:OPN用リバースプライマー
配列番号7:BSP用フォーワードプライマー
配列番号8:BSP用リバースプライマー
配列番号9:Collagen 1用フォーワードプライマー
配列番号10:Collagen 1用リバースプライマー
配列番号11:GAPDH用フォーワードプライマー
配列番号12:GAPDH用リバースプライマー
配列番号13:コラーゲンα-1 (I) 鎖プリカーサー
配列番号14:コラーゲンα-1 (II) 鎖プリカーサー
配列番号15:コラーゲンα-1 (XXVII) 鎖プリカーサー
配列番号16:コラーゲンα-2 (I) 鎖プリカーサー
配列番号17:フィブロネクチン
配列番号18:フィブロネクチン
配列番号19:デコリン
配列番号20:デコリン
配列番号21:オステオカルシン
配列番号22:オステオポンチン
配列番号23:骨シアロタンパク質 2
配列番号24:血管上皮成長因子 A
Claims (25)
- 5~15%の血清、50~150U/mLのペニシリン及び50~150μg/mLのストレプトマイシンを含有する培養液中に、5×103~5×104個/mLの骨髄間質細胞又は不死化乳歯幹細胞を加えて、34~37.5℃、5%CO2存在下に、予備培養を行う予備培養工程と;
所定の形状と接着性とを有する前記細胞を選別する細胞選別工程と;
前記選別工程で選別された細胞を予備培養と同じ条件で培養し、培養開始後40~56時間の培養上清を集める培養上清収集工程と;
を備える、細胞産生物の調製方法。 - 前記骨髄間質細胞は、ラットの大腿骨、ブタ歯髄、及びヒト乳歯からなる群から選ばれるいずれかの細胞に由来するものであることを特徴とする、請求項1に記載の細胞産生物の調製方法。
- 前記細胞を、37℃で培養することを特徴とする、請求項2に記載の細胞産生物の調製方法。
- 前記所定の形状は、スピンドル形状かつ紡錘型であることを特徴とする、請求項3に記載の細胞産生物の調製方法。
- 培養開始後44~52時間の前記培養上清を集めることを特徴とする、請求項1に記載の細胞産生物の調製方法。
- 培養開始後48時間の前記培養上清を集めることを特徴とする、請求項5に記載の細胞産生物の調製方法。
- 前記培養液は、ダルベッコ培地、イスコフ改変ダルベッコ培地、ハムF12培地、及びRPMI1640培地からなる群から選ばれる少なくとも1種以上の培地であることを特徴とする、請求項1に記載の細胞産生物の調製方法。
- 前記血清は、ウシ胎児血清、ウシ血清、ウマ血清、ヒト血清、及びヒツジ血清からなる群から選ばれる少なくとも1種以上の血清であることを特徴とする、請求項7に記載の細胞産生物の調製方法。
- 前記培養液は、10%ウシ胎児血清と、100U/mLのペニシリンと100μg/mLのストレプトマイシンとを含むことを特徴とする、請求項1に記載の細胞産生物の調製方法。
- 遠心及びエタノール沈殿処理を行って沈殿物を調製する沈殿物調整工程と;
前記沈殿物調製工程で得られた沈殿物を凍結乾燥させる凍結乾燥工程と;
をさらに備える、請求項1~9のいずれかに記載の細胞産生物の調製方法。 - 請求項1~10のいずれかに記載の方法で調製された細胞産生物。
- 前記培養上清には、少なくとも、I型コラーゲン(Col-I)、フィブロネクチン、デコリン及び血管内皮増殖因子(VEGF)が含まれることを特徴とする、請求項11に記載の細胞産生物。
- 前記培養上清には、インスリン様成長因子結合タンパク質7、フォリスタチン関連タンパク質、メタロプロテイナーゼインヒビターI、組織プラスミノーゲンアクチベーターインヒビター、アクチン、及びスルフヒドリルオキシダーゼIがさらに含まれることを特徴とする、請求項12に記載の細胞産生物。
- 前記培養上清には、SPARC、コラーゲンα2(IV)鎖、β-2-ミクログロブリン、Rho GTPase活性化タンパク質18がさらに含まれることを特徴とする請求項13に記載の細胞産生物。
- インプラント材の表面を有機溶媒で洗浄し、洗浄インプラント材とする洗浄工程と;
前記洗浄インプラント材を、所定の組成を有する第1石灰化溶液中に所定の温度で3~6時間浸漬し、浸漬インプラント材とする浸漬工程と;
前記浸漬インプラント材を所定の濃度の請求項12~14のいずれかに記載の細胞産生物を含有する第2石灰化溶液で2~5日間インキュベート処理する処理工程と;
を備えることを特徴とする、高機能インプラントの作成方法。 - 前記インプラント材は、チタン、ジルコニア、ハイドロキシアパタイト、及びβ‐TCPからなる群から選ばれるいずれかの材料で形成されていることを特徴とする、請求項16に記載の高機能インプラントの作成方法。
- 前記有機溶媒は、アセトンと60~80%エタノールであることを特徴とする、請求項16に記載の高機能インプラントの作成方法。
- 前記第1石灰化溶液は、100~150 mM NaCl, 2.5~3.5 mM CaCl2・H2O, 1.5~2.5 mM K2HPO4, 25~75 mM Tris-HCl(pH 7.2~7.6)であり、第2石灰化溶液は、130~160 mM KNO3, 1~2 mM Ca(NO3)2・4H2O, 0.5~1.5 mM K2HPO4(pH 7.0~7.8)であることを特徴とする、請求項16に記載の高機能インプラントの作成方法。
- 前記第1石灰化溶液は、136.8 mM NaCl, 3.10 mM CaCl2・H2O, 1.86 mM K2HPO4, 50 mM Tris-HCl(pH 7.4)であり、第2石灰化溶液は、142.8 mM KNO3, 1.5 mM Ca(NO3)2・4H2O, 0.9 mM K2HPO4(pH 7.4)であることを特徴とする、請求項18に記載の高機能インプラントの作成方法。
- 前記所定の温度が36~38℃であり、浸漬時間が4時間であることを特徴とする、請求項16に記載の高機能インプラントの作成方法。
- 前記所定の濃度の細胞産生物は、5~20mg/mLの濃度であることを特徴とする、請求項15に記載の高機能インプラントの作成方法。
- 請求項15~21のいずれかに記載の方法で作成された高機能インプラント。
- 少なくとも、I型コラーゲン(Col-I)、フィブロネクチン、及びデコリンを表面に保有することを特徴とする、請求項22に記載の高機能インプラント。
- インスリン様成長因子結合タンパク質7、フォリスタチン関連タンパク質、メタロプロテイナーゼインヒビターI、組織プラスミノーゲンアクチベーターインヒビター、アクチン、及びスルフヒドリルオキシダーゼIからなる群から選ばれる少なくとも1以上のタンパク質をさらに表面に有することを特徴とする、請求項23に記載の高機能インプラント。
- 前記高機能インプラントは、チタン、ジルコニア、ハイドロキシアパタイト、及びβ‐TCPからなる群から選ばれるいずれかの材料で形成されていることを特徴とする、請求項22に記載の高機能インプラント。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/655,990 US20160193387A1 (en) | 2012-12-26 | 2013-12-26 | Sophisticated Implant Material |
KR1020157020177A KR20150108843A (ko) | 2012-12-26 | 2013-12-26 | 고기능 임플란트 재료 |
JP2014554572A JP6033888B2 (ja) | 2012-12-26 | 2013-12-26 | 高機能インプラント材料 |
EP13868991.4A EP2940146A4 (en) | 2012-12-26 | 2013-12-26 | HIGH-FUNCTIONAL IMPLANT MATERIAL |
SG11201505045SA SG11201505045SA (en) | 2012-12-26 | 2013-12-26 | Sophisticated implant material |
CN201380072455.8A CN104981547A (zh) | 2012-12-26 | 2013-12-26 | 高功能植入体材料 |
HK15112003.3A HK1211321A1 (en) | 2012-12-26 | 2015-12-04 | Highly functional implant material |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-282001 | 2012-12-26 | ||
JP2012282001 | 2012-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014104246A1 true WO2014104246A1 (ja) | 2014-07-03 |
Family
ID=51021320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/084990 WO2014104246A1 (ja) | 2012-12-26 | 2013-12-26 | 高機能インプラント材料 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20160193387A1 (ja) |
EP (1) | EP2940146A4 (ja) |
JP (2) | JP6033888B2 (ja) |
KR (1) | KR20150108843A (ja) |
CN (1) | CN104981547A (ja) |
HK (1) | HK1211321A1 (ja) |
SG (1) | SG11201505045SA (ja) |
WO (1) | WO2014104246A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2017078176A1 (ja) * | 2015-11-05 | 2018-09-27 | 株式会社Quarrymen&Co. | 不死化幹細胞、及びその作製方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108295303A (zh) * | 2018-02-08 | 2018-07-20 | 中山大学附属第三医院(中山大学肝脏病医院) | 一种钛金属植入物及其制备方法和用途 |
CN111701071B (zh) * | 2020-06-28 | 2021-12-17 | 中国人民解放军国防科技大学 | 一种骨修复支架材料及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021456A1 (fr) * | 1998-10-13 | 2000-04-20 | Societe Anonyme Natural Implant | Procede et dispositif de preparation d'un implant dentaire par immersion dans une culture de cellules mesenchymateuses |
JP2004531461A (ja) | 2000-10-18 | 2004-10-14 | チルドレンズ メディカル センター コーポレーション | オステオポンチン被覆表面および使用方法 |
WO2011118795A1 (ja) * | 2010-03-26 | 2011-09-29 | 国立大学法人名古屋大学 | 損傷部治療用組成物 |
JP2012509750A (ja) | 2008-11-25 | 2012-04-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 機能性チタンインプラントおよびそれに類する再生可能材料 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1130971C (zh) * | 2000-07-13 | 2003-12-17 | 胡杰 | 制备用作细胞种植框架和植入体的生物细胞外基质的方法 |
US7192445B2 (en) * | 2000-12-06 | 2007-03-20 | Astra Tech Ab | Medical prosthetic devices and implants having improved biocompatibility |
AU2005318938B2 (en) * | 2004-12-24 | 2011-04-21 | Anteris Aus Operations Pty Ltd | An implantable biomaterial and a method of producing same |
US20090238853A1 (en) * | 2008-03-21 | 2009-09-24 | 3D Biotek, Llc | Hybrid Biomedical Device Fabricated From Biomaterials and Coated With a Natural Extra Cellular Matrix (ECM) Coating |
IN2014DN08862A (ja) * | 2012-03-28 | 2015-05-22 | Quarrymen Corp |
-
2013
- 2013-12-26 EP EP13868991.4A patent/EP2940146A4/en not_active Withdrawn
- 2013-12-26 US US14/655,990 patent/US20160193387A1/en not_active Abandoned
- 2013-12-26 WO PCT/JP2013/084990 patent/WO2014104246A1/ja active Application Filing
- 2013-12-26 CN CN201380072455.8A patent/CN104981547A/zh active Pending
- 2013-12-26 SG SG11201505045SA patent/SG11201505045SA/en unknown
- 2013-12-26 KR KR1020157020177A patent/KR20150108843A/ko not_active Application Discontinuation
- 2013-12-26 JP JP2014554572A patent/JP6033888B2/ja active Active
-
2015
- 2015-12-04 HK HK15112003.3A patent/HK1211321A1/xx unknown
-
2016
- 2016-10-26 JP JP2016209447A patent/JP2017061486A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021456A1 (fr) * | 1998-10-13 | 2000-04-20 | Societe Anonyme Natural Implant | Procede et dispositif de preparation d'un implant dentaire par immersion dans une culture de cellules mesenchymateuses |
JP2004531461A (ja) | 2000-10-18 | 2004-10-14 | チルドレンズ メディカル センター コーポレーション | オステオポンチン被覆表面および使用方法 |
JP2012509750A (ja) | 2008-11-25 | 2012-04-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 機能性チタンインプラントおよびそれに類する再生可能材料 |
WO2011118795A1 (ja) * | 2010-03-26 | 2011-09-29 | 国立大学法人名古屋大学 | 損傷部治療用組成物 |
Non-Patent Citations (8)
Title |
---|
FERGUSON S.J. ET AL.: "Biomechanical comparison of different surface modifications for dental implants", INT. J. ORAL. MAXILLOFAC. IMPLANTS, vol. 23, no. 6, December 2008 (2008-12-01), pages 1037 - 1046, XP055263530 * |
LI L. ET AL.: "Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure", MOL. BIOL. REP., vol. 36, no. 4, April 2009 (2009-04-01), pages 725 - 731, XP019684682 * |
LIU K. ET AL.: "The interactions between brain microvascular endothelial cells and mesenchymal stem cells under hypoxic conditions", MICROVASC. RES., vol. 75, no. 1, January 2008 (2008-01-01), pages 59 - 67, XP022397797 * |
MA M. ET AL.: "Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/ CXCR4 and SDF-1/CXCR7 signaling", CANCER LETT., vol. 312, no. 1, 15 December 2011 (2011-12-15), pages 1 - 10, XP028304197 * |
OSUGI M. ET AL.: "Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects", TISSUE ENG. PART A, vol. 18, no. 13-14, July 2012 (2012-07-01), pages 1479 - 1489, XP055263521 * |
PSALTIS P.J. ET AL.: "Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations", J. CELL. PHYSIOL., vol. 223, no. 2, pages 530 - 540, XP055150133 * |
SAKAI K. ET AL.: "Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuro-regenerative mechanisms", J. CLIN. INVEST., vol. 122, no. 1, pages 80 - 90, XP055263514 * |
See also references of EP2940146A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2017078176A1 (ja) * | 2015-11-05 | 2018-09-27 | 株式会社Quarrymen&Co. | 不死化幹細胞、及びその作製方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2014104246A1 (ja) | 2017-01-19 |
EP2940146A1 (en) | 2015-11-04 |
US20160193387A1 (en) | 2016-07-07 |
JP6033888B2 (ja) | 2016-11-30 |
KR20150108843A (ko) | 2015-09-30 |
SG11201505045SA (en) | 2015-08-28 |
HK1211321A1 (en) | 2016-05-20 |
JP2017061486A (ja) | 2017-03-30 |
CN104981547A (zh) | 2015-10-14 |
EP2940146A4 (en) | 2016-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Reprogramming of mesenchymal stem cells derived from iPSCs seeded on biofunctionalized calcium phosphate scaffold for bone engineering | |
JP5753545B2 (ja) | 間葉系前駆細胞(mpc)の増殖および/または生存を増強させる方法 | |
Wang et al. | Promotion of cardiac differentiation of brown adipose derived stem cells by chitosan hydrogel for repair after myocardial infarction | |
Lee et al. | Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2 | |
Mao et al. | Effect of micro-nano-hybrid structured hydroxyapatite bioceramics on osteogenic and cementogenic differentiation of human periodontal ligament stem cell via Wnt signaling pathway | |
Zhang et al. | Combination of scaffold and adenovirus vectors expressing bone morphogenetic protein-7 for alveolar bone regeneration at dental implant defects | |
Liu et al. | The stimulation of adipose-derived stem cell differentiation and mineralization by ordered rod-like fluorapatite coatings | |
Mazzoni et al. | Enhanced osteogenic differentiation of human bone marrow-derived mesenchymal stem cells by a hybrid hydroxylapatite/collagen scaffold | |
JP6351799B2 (ja) | 癌治療用医薬組成物の製造方法及びその方法によって製造された癌治療用医薬組成物 | |
Liu et al. | Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement | |
Kim et al. | Adult stem cells derived from human maxillary sinus membrane and their osteogenic differentiation | |
Fu et al. | Matrigel scaffolding enhances BMP9-induced bone formation in dental follicle stem/precursor cells | |
JP2006289062A (ja) | 肥大化能を有する軟骨細胞と足場を用いた骨補填材料 | |
JP2010268715A (ja) | 乳歯歯髄幹細胞に特徴的な遺伝子発現群の利用 | |
JP2017061486A (ja) | 高機能インプラント材料 | |
CN109504710B (zh) | Kdm4d的用途 | |
JP5454980B2 (ja) | 間葉系細胞増殖促進剤およびそれを含有する骨格系生体材料 | |
Che et al. | Bifunctionalized hydrogels promote angiogenesis and osseointegration at the interface of three-dimensionally printed porous titanium scaffolds | |
Ramenzoni et al. | Similar inductive effects of enamel and dentin matrix derivatives on osteoblast-like cell response over SLA titanium surface | |
Park et al. | Effect of FGF-2 on collagen tissue regeneration by human vertebral bone marrow stem cells | |
JP2007505621A (ja) | 骨誘導タンパク質及びペプチドの細胞内送達 | |
US10149922B1 (en) | Engineered collagen matrices for myocardial therapy | |
Lingling et al. | Recombinant human bone morphogenetic protein-7 enhances bone formation ability of jaw bone defect using human umbilical cord mesenchymal stem cells combined with nano-hydroxyapatite/collagen/poly (L-lactide) | |
Al-hashimi | Investigating the effect of the amelogenin peptide C11 on differentiation of stem cells of the apical papilla (SCAP) toward an odontoblastic phenotype: A pilot study in regenerative endodontics | |
Li et al. | Adipose-Derived Stromal Cells (ADSCs) Promote Bone Formation In Vivo Not by Transforming to Osteoblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13868991 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2014554572 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14655990 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2013868991 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013868991 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157020177 Country of ref document: KR Kind code of ref document: A |